Formulation and Evaluation of Nizatiding Floatince Table. by Sreekanth, Yetukuri
FORMULATION AND EVALUATION OF NIZATIDING FLOATINCE
TABLES
Y.SREEKANTH
26104509
DEPARTMENT OF PHARMACEUTIES
K.K COLLEGE OF PHARMACY,
GERUGAMBAKKAM, CHENNAI, 600122
     TAMIL NADU
MAY 2012
                                                     LIST OF CONTENTS
                                                                                                                                     PAGENO
1. INTRODUCTION                                                                                                           1     
    1.1. GASTRORETENTIVE DRUG DELIVERY SYSTEM                                            2  
    1.2. PHARMACOKINETIC ASPECTS                                                                           3  
       1.2.1. Absorption window
       1.2.2. Enhanced bioavailability
       1.2.3. Enhanced first pass biotransformation
       1.2.4. Improved bioavailability due to reduced p-glycoprotein activity in the duodenum
       1.2.5. Reduced frequency of dosing
       1.2.6. Targeted therapy for local ailments in the upper GI tract
   1.3. PHARMACODYNAMIC ASPECTS                                                                          4    
       1.3.1. Reduced fluctuations of drug concentration
      1.3.2. Improved selectivity in receptor activation    
      1.3.3. Reduced counter-activity of the body
      1.3.4. Extended time over critical (effective) concentration
      1.3.5. Minimized adverse activity at the colon
    1.4. PHYSIOLOGICAL CONSIDERATIONS                                                                                6
        1.4.1. Stomach physiology                                                                                                                   7
      1.4.2. Gastric PH                                                                                                                                                    9
      1.5. FACTORS AFFECTING THE GRDDS                                                                    9
      1.6. ADVANTAGES OF GRDDS                                                                                   10
     1.7. DISADVANTAGES OF GRDDS                                                                            11
     1.8. LIMITATIONS                                                                                                        11
     1.9. APPROACHES TO GASTRIC RETENTION                                                       12-24
         1.9.1. Floating drug delivery systems
         1.9.2. Bio adhesive systems
         1.9.3. Raft-forming systems
         1.9.4. High density systems
         1.9.5. Low density systems
         1.9.6. Expandable systems
            1.9.7. Swellable System
         1.9.8. Super porous hydrogels
         1.9.9. Magnetic system
2. LITERARURE REVIEW                                                                                                 25 
3. AIM & OBJECTIVE                                                                                                         35
4. PLAN OF WORK                                                                                                              36 
5. MATERIALS AND METHODS
    5.1. MATERIALS                                                                                                               37
      5.1.1. DRUG –EXCIPIENT PROFILE                                                                        38-47
         5.1.1.1. DRUG PROFILE
          5.1.1.2. EXCIPIENT PROFILE                                                                               
      5.1.2. EQUIPMENT USED                                                                                               37
     5.2. METHODS
       5.2.1. PREFORMULATION STUDIES                                                                           48
       5.2.2. EVALUATION OF FINAL BLEND                                                                      50
       5.2.3 ANALYTICAL METHODS                                                                                    52 
       5.2.4. PREPARATION OF NIZATIDINE FLOATING TABLETS                                52  
       5.2.5. EVALUATION OF NIZATIDINE FLOATING TABLETS                                 53   
 6.  THEORETICAL DOSE CALCULATION                                                                   56
 7. RESULTS AND DISCUSSION
       7.1. CALIBRATION CURVE OF NIZATIDINE                                                            58
       7.2. PREFORMULATION STUDIES                                                                              59
           7.2.1. SOLUBILITY OF NIZATIDINE IN 0.1 HCL                                   
           7.2.2. STABILITY OF NIZATIDINE IN 0.1 HCL
           7.2.3. DRUG-EXCIPIENT COMPATABILITY STUDIES                                        60  
              7.2.3.1. PHYSICAL INCOMPATABILITY STUDIES
              7.2.3.2. CHEMICAL INCOMPATABILITY STUDIES
                 7.2.3.2.1. Fourier Transform Infrared (FTIR) Spectroscopy
                 7.2.3.2.2. Differential Scanning Calorimetry (DSC)
         7.3. PHYSICAL PROPERTIES OF PREPARED POWDER BLENDS                     66
         7.4 EVALUATION OF PHYSICAL PARAMETERS OF FLOATING TABLET OF67
NIZATIDINE
         7.5. FLOATING PROPERTIES OF NIZATIDINE FLOATING TABLETS              67 
           7.6. IN VITRO DRUG RELEASE STUDIES OF PREPARED FORMULATIONS      68
           7.6.1. Release profiles of formulations containing HPMC K4M                                  68
           7.6.2. Release profiles of formulations containing Polyox WSR 1105                         70
         7.7. STABILITY STUDIES                                                                                            71
 
                                                       LIST OF TABLES
TABLE 
NO
                               TABLE  NAME   PAGE NO
    1.1 
    1.2 
    1.3
     5.1      
     5.2
     5.3 
     5.4
     5.5 
     5.6
     5.7   
      6.1
      7.1
       7.2
       7.3
       7.4
       7.5
       7.6
       7.7
       7.8
       7.9    
List of drugs formulated as single and multiple unit forms 
of GRDDS
Marketed products of GRDDS
Transit times of different dosage forms across the 
segments of GIT
Materials used in the study
Equipment used in the study
Physical incompatability
Scale of flow abilility
Flow properties and corresponding angles of repose 
Composition of nizatidine floating tablets containing HPMC
K4M&Polyox WSR 1105
Weight variation tolerances for uncoated tablets
Theoretical release profile of nizatidine
Absorbance of nizatidine against different concentrations 
at λmax
(314 nm) in 0.1 N HCl
Absorbance of nizatidine at different time points
Infra-Red band assignments for nizatidine
Physical properties of powder blends of tablet 
formulations
Post compression parameters of nizatidine floating tablets
Floating properties of nizatidine floating tablets
Cumulative percentage drug release of formulations 
containing citric acid & HPMC K4M
Cumulative percentage drug release of formulations with 
polyox WSR 1105
Stability studies of F6 formulation
       5
       6 
       8 
       36
       36
       48
       51
       51 
       53
       54
       57
       58
       60
       61  
       66
       67
       67
       68
       70
         
       
FIGURE
    NO
                                   FIGURE NAME  PAGE NO
      1.1  
      1.2
      1.3  
      1.4
       1.5  
       1.6  
       1.7
      1.8 
      1.9 
      1.10
       1.11
       1.12  
       1.13
       1.14
       1.15
       1.16 
       1.17
       1.18 
                
Drug absorption in the case of (a) conventional dosage 
forms and (b) gastroretentive drug delivery systems
Anatomy of stomach
Schematic representation of interdigestive motility pattern
Mechanism of floating system
Working Principle of Non-Effervescent Type (HBS - 
Hydrodynamically balanced system) of FDDS
Gas-generating systems. Schematic monolayer drug 
delivery system (a), Bilayer gas-generating systems, with 
(c) or without (b) semipermeable membrane
Schematic representation of ‘‘floating pill’’  (a), The 
penetration of water into effervescent layer leads to a CO2 
generation and makes the system to float (b).
Pictorial presentation of working of effervescent floating 
drug delivery system based on ion exchange resin
Intra gastric floating gastrointestinal drug delivery device
Inflatable gastrointestinal delivery system
Intragastric osmotically controlled drug delivery system
Schematic illustration of mucoadhesive systems
Schematic illustration of the barrier formed by a raft-
forming system
Illustration representing (A): the systems based on high 
density.
(B): the systems based on low density
a) Microballoons, (b) Foam-particles
Different geometric forms of expandable systems
Swellable systems developed by (a)Mamajek and Moyer,
(b) Urquhart and Theeuwes
On the left, (a) superporous hydrogel in its dry and (b) 
water-swollen state.
On the right, schematic illustration of the transit of 
superporous hydrogel
        3
        7 
        8
        13
        14  
        16
        17
        18  
        18
        19
        20
        20
        21
 
        21
        
        22
        23
         
        23 
        24
       7.1
       7.2
       7.3 
       7.4   
       7.5
       7.6
       7.7
       7.8
       7.9
       
 
Calibration curve of nizatidine in 0.1N HCl at 314 nm
Comparison of FT-IR spectra of pure nizatidine (a), HPMC 
K4M & nizatidine mixture (1:1) immediately after 
preparation (b) and after one month preservation at room 
temperature (f)
Comparison of FT-IR spectra of pure nizatidine (a), polyox 
WSR 1105 & nizatidine mixture (1:1) immediately after 
preparation (c) and after one month preservation at room 
temperature (g)
Comparison of FT-IR spectra of pure nizatidine (a), citric 
acid anhydrous & nizatidine mixture (1:1) immediately 
after preparation (d) and after one month preservation at 
room temperature (h)
DSC curves of pure drug nizatidine (NIZ-1), pure polymer 
HPMC K4M (NIZ-5) and 1:1 mixture of nizatidine & HPMC 
K4M (NIZ-7)
DSC curves of nizatidine pure drug (NIZ-1), pure polymer 
polyox WSR 1105 (NIZ-6) and 1:1 mixture of nizatidine & 
polyox WSR 1105 (NIZ-8)
DSC curves of nizatidine pure drug (NIZ-1), pure citric acid 
anhydrous (NIZ-2), 1:1 mixture of nizatidine & citric acid 
immediately after preparation (NIZ-3) and after one month
preservation at room temp. (NIZ-4)
Cumulative percentage drug release profiles of F2, F3,  
formulations containing HPMC K4M
Cumulative percentage drug release profiles of 
formulations containing Polyox WSR 1105
       60
       61 
       62
       63
       64
       64
       65
       69
       70
LIST OF ABBREVIATIONS
GIT :- Gastro Intestinal Tract
CR-GRDF :- Controlled Release Gastroretentive Dosage Form
NAW :- Narrow Absorption Window
GRT :- Gastric Residence Time
GRDF :- Gastro Retentive Dosage Form
CYP :- Cytochrome P
P-gp :- Pearmeability glycoprotein
CR :- Controlled Release
MMC :- Migrating Myloelectric Cycle
KSI :- kilo pounds per square inch
FDDS :- Floating Drug Delivery System
HPMC :- Hydroxy Propyl Methyl Cellulose
HEC :- Hydroxyl Ethyl Cellulose
Na CMC :- Sodium Carboxy Methyl Cellulose
HPC :- Hydroxyl Propyl Cellulose
HBS :- Hydrodynamically Balanced System
PUD :- Peptic Ulcer Disease
GERD :- Gastro Esophageal Reflux Disease
FTIR :- Fourier Transform Infra Red
DSC :- Differential Scanning Calorimetry
b.i.d. :- bis in die (twice daily)
MPas :- milli Pascal seconds
MCC :- Micro Crystalline Cellulose
UV :- Ultra-Violet
1. INTRODUCTION1
Currently, in the field of pharmaceutical technology, great efforts are being directed
towards the refabrication of existing drug molecules in a fashion, capable of solving problems
related to poor water solubility, poor bioavailability, dosing problem, stability, toxicity, etc.
This trend of working has led to development of new drug delivery system.
Basic goal of drug therapy is to provide therapeutic amount of drug to proper site in
the body to promptly achieve and then maintain desired drug concentration. This idealized
objective points to two aspects most important to the drug delivery, namely, spatial placement
and temporal delivery of drug. Spatial placement relates to targeting a drug to specific organ
or tissue while temporal delivery refers to controlling rate of drug delivery to that specific
organ or tissue.
Despite tremendous advancement in drug delivery, oral route remains preferred route
for  administration.  Even  today,  conventional  drug  delivery  systems  are  primary
pharmaceutical products commonly seen in prescriptions and ‘over the counter’ market place.
They provide prompt release of the drug but in order to achieve as well as maintain drug
concentration within therapeutically achieved range,  it  is  often necessary to administer  it
several times a day. This results in significant fluctuations of drug concentration in systemic
circulation causing either lethal effect or no therapeutic action. 
Oral controlled release dosage forms have been developed over past three decades.
These  drug  delivery systems  have  a  great  potential  of  solving  problems  associated  with
conventional  multiple  dosing  system  like  strict  adherence  to  timely  dosing,  plasma
concentration  fluctuations,  associated  side  effects  due  to  systemic  accumulation  of  drug.
Thus, there are numerous advantages such as improved efficacy, reduced toxicity, improved
patient compliance and convenience, reduction in health care cost, etc.
However, this approach is facing problems with several physiological difficulties such
as inability to restrain and locate controlled drug delivery system within the desired region of
GIT, due to variable gastric emptying and motility.  Furthermore,  the relative brief gastric
emptying time in humans which normally averages 2-3 hours through major absorption zone
i.e.,  stomach and upper  part  of intestine can result  in incomplete drug release from drug
delivery system leading to low bioavailability and thus reduced efficacy of administered dose.
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It is evident from the recent scientific and patent literature that an increased interest in
novel dosage forms that are retained in stomach for prolonged and predictable period of time
exists today in academic and industrial research groups. One of the most feasible approaches
for achieving a prolonged and predictable drug delivery profile in GIT is to control gastric
residence time.
Control  of  placement  of  drug  delivery  system  in  specific  region  of  GIT  offers
advantage for variety of important drugs characterized by narrow absorption window in GIT
or drugs with stability problem. These considerations have led to development of unique oral
controlled release dosage form with gastro retentive properties i.e.,  dosage form could be
retained in  the stomach for  several  hours  and  release the drug there in  a  controlled  and
prolonged manner, so that drug could be supplied continuously to its absorption site in the
upper GIT.
1.1. GASTRORETENTIVE DRUG DELIVERY SYSTEM
Gastroretentive dosage forms are drug delivery systems which remain in the stomach
for an extended period of time and allow both spatial and time control of drug liberation.
Basically  gastroretentive  systems  retain  in  the  stomach  for  a  number  of  hours,  while  it
continuously releases the incorporated drug at a controlled rate to preferred absorption sites
in  the  upper  intestinal  tract.  Their  application  can  be  advantageous  in  the  case  of  drugs
absorbed mainly from the upper part of GIT or drugs which are unstable in the medium of
distal  intestinal  regions.  They  can  also  be  used  beneficially  in  the  local  therapy  of  the
stomach. Prolonged gastric retention of the drugs may offer numerous advantages including
improved bioavailability, therapeutic efficacy and possible reduction of dosage size.
Suitable drugs for gastro retentive drug delivery systems2 
 Narrow absorption window in GI tract
e.g., riboflavin, levodopa, para-aminobenzoic acid, furosemide.
 Primarily absorbed from stomach and upper part of GI tract
            e.g., calcium supplements, chlordiazepoxide and cinnarizine.
 Drugs that act locally in the stomach
e.g., antacids and misoprostol.
 Drugs that degrade in the colon
e.g., ranitidine HCl and captopril.
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 Drugs that disturb normal colonic bacteria
e.g., antibiotics against Helicobacter pylori (amoxicillin trihydrate).
Incorporation of the drug in a controlled release gastroretentive dosage forms (CR-
GRDF) can yield significant therapeutic advantages due to a variety of pharmacokinetic and
pharmacodynamic factors.
1.2 PHARMACOKINETIC ASPECTS3
1.2.1. Absorption window
Figure 1.1: Drug absorption in the case of (a) conventional dosage formsand (b)
gastroretentive drug delivery systems
Some of the drugs are characterized by a narrow absorption window (NAW) at the
upper  part  of  the  GIT.  This  is  because  the  proximal  part  of  the  small  intestine  exhibits
extended absorption properties (including larger gaps between the tight junctions, and dense
active  transporters).  Despite  the  extensive  absorption  properties  of  the  duodenum  and
jejunum, the extent of absorption at these sites is limited because the passage through this
region is rapid. Enhancing the gastric residence time (GRT) of a NAW drug may significantly
improve the net extent of its absorption.
3
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1.2.2. Enhanced bioavailability
Once it has been ascertained that the compound in question is defined as NAW, there
is  a  possibility  for  improving  oral  bioavailability  by  continuous  administration  of  the
compound to the specific site. The bioavailability of riboflavin and levodopa CR-GRDF is
significantly  enhanced  in  comparison  to  administration  of  non-GRDF  CR  polymeric
formulations.
1.2.3. Enhanced first pass biotransformation
In a similar fashion to increased efficacy of active transporters exhibiting capacity
limited activity, the pre-systemic metabolism of the tested compound may be considerably
increased  when  the  drug  is  presented  to  the  metabolic  enzymes  (cytochrome  P450,  in
particular CYP3A4) in a sustained manner, rather than by a bolus input.
1.2.4. Improved bioavailability due to reduced P-glycoprotein (P-gp) activity in
the duodenum
In apparent contrast to the higher density of CYP3A4 at the upper part of the intestine,
P-gp mRNA levels increase longitudinally along the intestine such that the highest levels are
located in the colon. Therefore, for drugs that are P-gp substrate and do not undergo oxidative
metabolism, such as digoxin, CR-GRDF may elevate absorption compared to the immediate
and CR dosage forms.
1.2.5. Reduced frequency of dosing
For drugs with relatively short biological half-life, sustained and slow input from CR-
GRDF may result in a flip-flop pharmacokinetics and enable reduced dosing frequency. This
feature is associated with improved patient compliance, and thereby improves therapy.
1.2.6. Targeted therapy for local ailments in the upper GI tract
The  prolonged  and  sustained  administration  of  the  drug  from  the  GRDF  to  the
stomach may be advantageous for local therapy in the stomach and the small intestine. By
this mode of administration, therapeutic drug concentrations may be attained locally while
the systemic concentrations, following drug absorption and distribution, are minimal.
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1.3. PHARMACODYNAMIC ASPECTS
1.3.1. Reduced fluctuations of drug concentration
Continuous  input  of  the drug  following CR-GRDF administration  produces  blood
drug  concentrations  within  a  narrower  range  compared  to  the  immediate  release  dosage
forms. Thus, fluctuations in drug effects are minimized and concentration dependent adverse
effects  that  are  associated  with  peak  concentrations  can  be  prevented.  This  feature  is  of
special importance for drugs with a narrow therapeutic index.
1.3.2. Improved selectivity in receptor activation
Minimization of fluctuations in drug concentration also makes it possible to obtain
certain selectivity in the elicited pharmacological effect of drugs that activate different types
of receptors at different concentrations.
1.3.3. Reduced counter-activity of the body
In  many  cases,  the  pharmacological  response  which  intervenes  with  the  natural
physiologic processes provokes a rebound activity of the body that minimizes drug activity.
Slow input of the drug into the body was shown to minimize the counter activity leading to
higher drug efficiency.
1.3.4. Extended time over critical (effective) concentration
For certain drugs that have non-concentration dependent pharmacodynamics, such as
β-lactam antibiotics,  the  clinical  response  is  not  associated  with  peak  concentration,  but
rather, with the duration of time over a critical therapeutic concentration. The sustained mode
of  administration  enables  extension  of  the  time  over  a  critical  concentration  and  thus
enhances the pharmacological effects and improves the clinical outcomes.
1.3.5. Minimized adverse activity at the colon
Retention of the drug in the GRDF at the stomach minimizes the amount of drug that
reaches the colon. Thus, undesirable activities of the drug in colon may be prevented. This
pharmacodynamic  aspect  provides  the  rationale  for  GRDF  formulation  for  β-lactam
antibiotics that are absorbed only from the small intestine, and whose presence in the colon
leads to development of microorganism’s resistance. 
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Table 1.1: List of drugs formulated as single and multiple unit forms of GRDDS 4
S.NO Dosage form Drugs
1 Microspheres
Metformin  hydrochloride,  Ketoprofen,  Aspirin,  Verapamil,
Griseofulvin, p-nitroaniline, Ibuprofen, Terfenadine, Tranilast.
2 Granules Diclofenac sodium, Indomethacin, Prednisolone.
3 Films Cinnarizine
4 Capsules
ChlordiazepoxideHCl,  Diazepam,  Furosemide,  L-Dopa  and
Benserazide,  Misoprostol,  Propranolol  HCl,  Ursodeoxycholic
acid, Nicardipine.
5 Tablets/Pills
Phenytoin,  5-fluorouracil,  Furosemide,  Ciprofloxacin,
pentoxyfillin,  Atenolol,  Amoxicillin  trihydrate,  Ampicillin,
Atenolol,  Chlorpheniramine,  Cinnarizine,  Diltiazem,
Fluorouracil, Isosorbidemononitrate, Isosorbidedinitrate, p-amino
benzoic acid, Piretanide, Prednisolone, Quinidine gluconate.
Table 1.2: Marketed Products of GRDDS 
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Brand name Delivery system Drug (dose) Company name
Valrelease® Floating capsule Diazepam (15mg) Hoffmann-
LaRoche, USA
Madopar® HBS 
(Prolopa® HBS)
Floating, CR capsule Benserazide (25mg) 
and L-Dopa (100mg)
Roche Products, 
USA
Liquid 
Gaviscon®
Effervescent Floating 
liquid  alginate 
preparations
Al hydroxide (95 mg), 
Mg Carbonate (358 
mg)
GlaxoSmithKline, 
India
Topalkan® Floating liquid  alginate
preparation
Al – Mg  antacid Pierre Fabre Drug, 
France
Conviron® Colloidal gel forming 
FDDS
Ferrous sulphate Ranbaxy, India
Cytotech® Bilayer floating capsule Misoprostol 
(100µg/200µg)
Pharmacia, USA
1.4. PHYSIOLOGICAL CONSIDERATIONS
It  is  recognized  that  there  are  many  physiological  constraints,  which  may  limit
development of such delivery systems. Factors such as pH, enzymes, nature and volume of
secretions, residence time and effective absorbing surface area of the site of delivery play an
important  role  in  drug  liberation  and  absorption.  Nevertheless,  in  vivo studies  of  certain
systems have shown promising results.
1.4.1. Stomach physiology
The stomach is divided into 3 anatomic regions: fundus, body, and antrum (pylorus).
The part made of fundus and body act as a reservoir for undigested material, whereas the
antrum is  the  main  site  for  mixing  motions  and  act  as  a  pump for  gastric  emptying  by
propelling  actions.  The  separation  between  stomach  and  duodenum  is  the  pylorus.  The
pylorus, due to its size, plays a major role in gastric residence time of GRDF. 
The stomach volume is about 1.5 L after a meal and in range of 250 - 500 mL in
interdigestivephases, it produces 2 L among the 8 L of all liquid present in gastro intestinal
tract.
Figure 1.2: Anatomy of
stomach
Gastric emptying  is  the
way out  for the  bolus  and
occurs during  fasting  as
well  as  fed states.  The  pattern
of  motility is  however  distinct
for  the  two states,  the  motility
is  stronger in  fasting  mode
than in fed mode. During the fasting state an interdigestive series of electrical events take
place,  which cycle both through stomach and intestine every 2 to 3 h.  This is  called the
interdigestivemyloelectric  cycle or  migrating myloelectric  cycle (MMC).  which is  further
divided into following 4 phases.
 Phase I (basal phase) lasts from 30 to 60 min with rare contractions.
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 Phase II (preburst phase) lasts from 20 to 40 min with intermittent action potential and
contractions. As the phase progresses the intensity and frequency also increases gradually.
 Phase III (burst phase) lasts for 10 to 20 min. It includes intense and regular contractions
for short period. It is due to this wave that all the undigested material is swept out of the
stomach down to the small intestine. It is also known as the housekeeper wave.
 Phase IV lasts for 0 to 5 min is a transition period of decreasing activity until the next
cycle begins.
Figure 1.3: Schematic representation of interdigestive motility pattern 
Table 1.3: Transit times of different dosage forms across the segments of GIT 
Dosage form
Transit time (hours)
Gastric Small intestine Total
Tablets 2.7±1.5 3.1±0.4 5.8
Pellets 1.2±1.3 3.4±1.0 4.6
Capsules 0.8±1.2 3.2±0.8 4.0
Solution 0.3±0.07 4.1±0.5 4.4
1.4.2. Gastric pH
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The gastric pH is not constant rather it is influenced by various factors such as diet, disease,
presence of gases, fatty acids and other fermentation products, however, the reported mean
value of gastric pH in fasted healthy subjects is 1.1±0.5 and in fed state basal gastric secretion
in women is slightly lower than that of men  (Mojoverian and Chan,1988). The pH in the
proximal duodenum may rise as high as 4 pH units from the stomach. This increase in pH is
caused by the bicarbonate secreted by the pancreas and the duodenal mucosa that neutralize
acidic chime peristalised from the stomach. The mean pH value in fasted duodenum has been
reported to be 5.8±0.3 in healthy subjects while the fasted small intestine has been observed
to have a mean pH of 6.0±0.14. Passing from jejunum through the mid small intestine and
ileum, pH rises from about 6.6 to 7.5.
1.5. FACTORS AFFECTING THE GRDDS5
Various attempts have been made to retain the dosage form in the stomach as a way of
increasing  the  retention time.  These  attempts  include  use  of  floating  dosage  forms  (gas-
generating systems and swelling or expanding systems), mucoadhesive systems, high-density
systems, modified shape systems, gastric emptying delaying devices and co-administration of
gastric-emptying delaying drugs. Most of these approaches are influenced by a number of
factors that affect their bioavailability and efficacy of the gastro retentive system.
• Density – Gastric retention time (GRT) is a function of dosage form buoyancy, which is
dependent on the density.
• Size – Dosage form units with a diameter of more than 7.5 mm are reported to have an
increased GRT compared with those with a diameter of 9.9 mm.
• Shape of dosage form – Tetrahedron and ring shaped devices with a flexural modulus of
48 and 22.5 kilo pounds per square inch (KSI) are reported to have better GRT 90% to
100% retention at 24 hours compared with other shapes.
• Single  or  multiple  unit  formulation –  Multiple  unit  formulations  show  a  more
predictable release profile and insignificant impairing of performance due to failure of
units,  allow  co-administration  of  units  with  different  release  profiles  or  containing
incompatible substances and permit a larger margin of safety against dosage form failure
compared with single unit dosage forms.
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• Fed or unfed state – Under fasting conditions, the GI motility is characterized by periods
of strong motor activity or the migrating myoelectric complex (MMC) that occurs every
1.5 to 2 hours. The MMC sweeps undigested material from the stomach and, if the timing
of administration of the formulation coincides with that of the MMC, the GRT of the unit
can be expected to be very short. However, in the fed state, MMC is delayed and GRT is
considerably longer.
• Nature of meal – Feeding of indigestible polymers or fatty acid salts  can change the
motility pattern of the stomach to a fed state, thus decreasing the gastric emptying rate
and prolonging drug release. 
• Caloric content – GRT can be increased by 4 to10 hours with a meal that is high in
proteins and fats.
• Frequency of feed – The GRT can increase by over 400 minutes when successive meals
are given compared with a single meal due to the low frequency of MMC.
• Gender – Mean ambulatory GRT in males (3.4±0.6 hours) is less compared with their
age  and  race  matched  female  counterparts  (4.6±1.2  hours),  regardless  of  the  weight,
height and body surface.
• Age – Elderly people, especially those over 70, have a significantly longer GRT.
• Posture – GRT can vary between supine and upright ambulatory states of the patient.
• Biological factors – Diabetes and Crohn’s disease, etc.
• Concomitant drug administration – Anti-cholinergics like atropine and propantheline,
opiates like codeine and prokinetic agents like metoclopramide and cisapridecan affect
floating time.
1.6. ADVANTAGES OF GRDDS
Gastro retentive drug delivery systems have numerous advantages listed below.
Floating  drug  delivery  offers  several  applications  for  drugs  having  poor
bioavailability  because  of  the  narrow  absorption  window  in  the  upper  part  of  the
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gastrointestinal tract. It retains the dosage form at the site of absorption and thus enhances the
bioavailability. These are summarized as follows:
1. Enhanced bioavailability
2. Sustained Drug Delivery / reduced frequency of dosing
3. Site-Specific Drug Delivery
4. Reduced fluctuations of drug concentration
5. Minimized adverse activity at the colon
6. Absorption Enhancement
1.7. DISADVANTAGES OF GRDDS
Gastro retentive drug delivery systems have some disadvantages listed below:
1. There are certain situations where gastric retention is not desirable. Aspirin and non-
steroidal anti-inflammatory drugs are known to cause gastric lesions and slow release
of such drugs in the stomach is unwanted.
2. Thus,  drugs  that  may  irritate  the  stomach  lining  or  are  unstable  in  its  acidic
environment should not be formulated in gastro retentive systems.
3. Furthermore, other drugs, such as isosorbide dinitrate, that are absorbed equally well
throughout the GI tract will not benefit  from incorporation into a gastric retention
system.
4. Gastric  retention  is  influenced  by  many factors  such  as  gastric  motility,  pH and
presence of food. These factors are never constant and hence the buoyancy cannot be
predicted exactly or accurately.
5. Gastric  emptying  of  floating  forms  in  supine  subjects  may occur  at  random and
become highly dependent on the diameter. Therefore, patients should not be dosed
with floating forms just before going to bed. 
6. High variability in gastric emptying time due to variations in emptying process.
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1.8. LIMITATIONS
Gastro retentive drug delivery systems have some limitations listed below:
1. The major disadvantage of floating system is requirement of a sufficient high level of
fluids in the stomach for the drug delivery to float. However, this limitation can be
overcome by coating the dosage form with the help of bioadhesive polymers  that
easily adhere to the mucosal lining of the stomach
2. Floating system is not feasible for those drugs that have solubility or stability problem
in gastric fluids.
3. The dosage form should be administered with a minimum of glass full of water (200-
250 mL).
4. The drugs, which are absorbed throughout gastro-intestinal tract, which under go first-
pass metabolism (e.g., nifedipine, propranolol etc.) are not desirable candidates.
5. Some drugs present in the floating system causes irritation to gastric mucosa.
1.9. APPROACHES TO GASTRIC RETENTION6
Various attempts have been made to retain the dosage form in the stomach as a way of
increasing the retention time. These attempts include:
• Floating  Drug  Delivery  System  (FDDS),  with  low  density  providing  sufficient
buoyancy to float over the gastric contents.
• Bioadhesive systems, enabling the localized retention of the system in the stomach.
• Swelling and expanding systems, preventing transit from the gastric sphincter.
• High  density  system,  remaining  in  the  stomach  for  longer  period  of  time  by
sedimenting to the folds of stomach.
• Superporous hydrogels.
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• Modified-shaped system.
A number of other methods like use of passage-delaying agents, magnetically controlled
systems and combination methods like floating-bioadhesive systems were also tried.
1.9.1. Floating drug delivery systems
The concept of FDDS was described in the literature as early as. FDDS have a bulk
density less than gastric fluids and so remain buoyant in the stomach without affecting the
gastric emptying rate for a prolonged period of time. While the system is floating on the
gastric contents the drug is released slowly at the desired rate from the system. This results in
an increased GRT and a better control of fluctuations in plasma drug concentration.
Figure 1.4: Mechanism of floating system 
Formulation of this device must comply with the following criteria:
 It must have sufficient structure to form a cohesive gel barrier.
 It must maintain an overall specific gravity lower than that of gastric contents (1.004-
1.010).
 It should dissolve slowly enough to serve as a drug reservoir. 
Types of floating drug delivery systems
Based on the mechanism of buoyancy and two distinctly different technologies have
been utilized in the development of FDDS.
1) Non- Effervescent FDDS
2) Effervescent FDDS 
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1.9.1.1. Non-Effervescent FDDS
Non-effervescent floating dosage forms use a gel forming or swellable cellulose type
of  hydrocolloids,  polysaccharides,  and  matrixforming  polymers  like  polycarbonate,
polyacrylate, polymethacrylate, and polystyrene. The formulation method includes a simple
approach  of  thoroughly  mixing  the  drug  and  the  gel-forming  hydrocolloid.  After  oral
administration this dosage form swells in contact with gastric fluids and attains a bulk density
of < 1. The air entrapped within the swollen matrix imparts buoyancy to the dosage form.
Thus formed swollen gel-like structure, acts as a reservoir and allows sustained release of
drug through the gelatinous mass.
Hydrodynamically Balanced systems:
These are single-unit dosage forms, containing one or more gel-forming hydrophilic
polymers. Hydroxy propyl methyl cellulose (HPMC) is the most commonly used excipient,
although hydroxyl ethyl cellulose (HEC), hydroxyl propyl cellulose (HPC), sodium carboxy
methyl cellulose (NaCMC), agar, carrageenans or alginic acid are also used. The polymer is
mixed with drug and usually administered in a gelatine capsule. The capsule rapidly dissolves
in the gastric fluid, and hydration and swelling of the surface polymers produces a floating
mass.  Drug release is  controlled by the formation of a hydrated boundary at  the surface.
Continuous erosion of the surface allows water penetration to the inner layers, maintaining
surface hydration and buoyancy (Figure 1.5).
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Figure 1.5: Working Principle of Non-Effervescent type (HBS-Hydrodynamically
balanced system) of FDDS 
1.9.1.2.Effervescent System
Effervescent systems include use of gas generating agents, carbonates (ex. Sodium
bicarbonate)  and  other  organic  acid  (e.g.  citric  acid  and  tartaric  acid)  present  in  the
formulation to produce carbon dioxide (CO2) gas, thus reducing the density of the system and
making it to float on the gastric fluid. An alternative is the incorporation of matrix containing
portion of liquid, which produces gas due to evaporation at body temperature.
These effervescent systems further are classified into two types:
A. Gas generating systems
B. Volatile Liquid/Vacuum Containing Systems
A.   Gas Generating Systems
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These are  matrix  type  of  systems  prepared  with  the  help  of  swellable  polymers  such as
methylcellulose and chitosan and various effervescent compounds, eg, sodium bicarbonate,
tartaric acid, and citric acid. They are formulated in such a way that when in contact with the
acidic gastric contents, CO2 is liberated and gets entrapped in swollen hydrocolloids, which
provide buoyancy to the dosage forms.
              In single unit systems, such as capsules or tablets, effervescent substances are
incorporated in the hydrophilic polymer, and CO2  bubbles are trapped in the swollen matrix
(Figure 1.6 a).  In vitro, the lag time before the unit floats is <1 min and the buoyancy is
prolonged for  8  to  10 hours.  In  vivo experiments  in  fasted  dogs showed a  mean gastric
residence time increased up to 4 hours. Bilayer or multilayer systems have also been design.
Drug  and  excipients  are  formulated  independently  and  the  gas  generating  unit  can  be
incorporated into any of the layers (Figure 1.6 b). Further refinements involve coating the
matrix with a polymer which is permeable to water, but not to CO2 ( (Figure 1.6 c). The main
difficulty of such formulation is to find a good compromise between elasticity, plasticity and
permeability of the polymer.
Figure 1.6: Gas-generating systems. Schematic monolayer drug delivery system (a) and
Bilayer gas-generating systems, with (c) or without (b) semipermeable membrane 
Multiple unit systems avoid the ‘‘all or nothing’’ emptying process. However, it is
essential that the units remain dispersed and suspended individually in the gastric fluid and
not agglomerate into a mass floating at the top of the stomach a double layered coated system
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in the form of granules (Figure 1.7). It comprised an inner effervescent layer (bicarbonate and
tartaric acid) and an outer swellable membrane (polyvinyl acetate and shellac). The system
floated completely within 10 min and 80% remained floating over a period of 5 hours.  In
vivo studies have been carried out in beagle dogs and humans in the fed state using granules
loaded with barium sulphate as a radio opaque marker. Most floated in the stomach within 10
min and remained so for at least 3 hours as observed by X-ray photography.
Figure 1.7: Schematic representation of ‘‘floating pill’’ (a),The penetration of water into
effervescent layer leads to a CO2 generation and makes the system to float (b).
A) Penetration of water into the device; B) generation of carbon dioxide and floating; and C)
dissolution of the drug. Key: a) Conventional sustained release core; b) effervescent layer; c)
swellable layer; d) expanded swellable membrane layer; e) water (37°C) surface in thebeaker.
A floating  system using  ion  exchange  resin  that  was  loaded  with  bicarbonate  by
mixing  the  beads  with  1M  sodium  bicarbonate  solution.  The  loaded  beads  were  then
surrounded by a semi permeable membrane to avoid sudden loss of CO2. Upon coming in
contact with gastric contents an exchange of chloride and bicarbonate ions took place, that
resulted in CO2 generation, thereby carrying beads towards the top of gastric contents and
producing a floating layer of resin beads. The  in vivo behavior of the coated and uncoated
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Upward movement of system due to CO
2
beads was monitored using a single channel analyzing study in 12 healthy human volunteers
by gamma radio scintigraphy. Studies showed that the gastric residence time was prolonged
considerably (24 hours) compared with uncoated beads (1 to 3 hours).
Figure 1.8: Pictorial presentation of working of effervescent floating drug delivery
system based on ion exchange resin 
B. Volatile Liquid / Vacuum Containing Systems
i. Intra-gastric floating gastrointestinal drug delivery system
These systems can be made to float in the stomach because of floatation chamber,
which may have a vacuum or filled with air  or an harmless  gas,  while  drug reservoir is
encapsulated inside a micro-porous compartment (Figure 1.9). 
Figure 1.9: Intra gastric floating gastrointestinal drug delivery device 
ii. Inflatable gastrointestinal delivery systems
In these systems an inflatable chamber is incorporated, which contains liquid ether
that  gasifies  at  body temperature  to  cause  the  chamber  to  inflate  in  the  stomach.  These
systems are fabricated by loading the inflatable chamber with a drug reservoir, which can be
a  drug  impregnated  polymeric  matrix,  encapsulated  in  a  gelatin  capsule.  After  oral
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Bioerodible polymer filament
administration, the capsule dissolves to release the drug reservoir together with the inflatable
chamber.  The  inflatable  chamber  automatically  inflates  and  retains  the  drug  reservoir
compartment in the stomach. The drug is continuously released from the reservoir into the
gastric fluid (Figure 1.10).
Figure 1.10: Inflatable gastrointestinal delivery system
iii. Intragastric osmotically controlled drug delivery system 
It  is  comprised  of  an  osmotic  pressure  controlled  drug  delivery  device  and  an
inflatable floating support in a biodegradable capsule. In the stomach, the capsule quickly
disintegrates  to  release  the  intra-gastric  osmotically  controlled  drug  delivery device.  The
inflatable support inside forms a deformable hollow polymeric bag that contains a liquid that
gasifies at body temperature to inflate the bag. The osmotic pressure controlled drug delivery
device consists of two components; drug reservoir compartment and an osmotically active
compartment.  The  drug  reservoir  compartment  is  enclosed  by  a  pressure  responsive
collapsible bag, which is impermeable to vapour and liquid and has a drug delivery orifice.
The  osmotically  active  compartment  contains  an  osmotically  active  salt  and  is  enclosed
within a semipermeable housing. In the stomach, the water in the GI fluid is continuously
absorbed  through  the  semipermeable  membrane  into  osmotically  active  compartment  to
dissolve the osmotically active salt. The osmotic pressure thus created acts on the collapsible
bag and in turn forces the drug reservoir compartment to reduce its volume and activate drug
release through the delivery orifice.
The floating support is also made to contain a bio-erodible plug that erodes after a
predetermined time to deflate the support. The deflated drug delivery system is then emptied
from the stomach.
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Drug reservoir
Capsule
Inflatable chamber
Figure 1.11:Intragastric osmotically controlled drug delivery system.
1.9.2. Bio adhesive systems7
Bioadhesive drug delivery systems are used as a delivery device within the human to
enhance drug absorption in a site-specific manner. In this approach, bio adhesive polymers
are used and they can adhere to the epithelial surface in the stomach . Thus, they improve the
prolongation of gastric retention.
Figure 1.12: Schematic illustration mucoadhesive systems 
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1.9.3. Raft-forming systems
Here, a gel-forming solution (e.g. sodium alginate solution containing carbonates or
bicarbonates) swells and forms a viscous cohesive gel containing entrapped CO2 bubbles on
contact with gastric fluid (Figure 1.13). Formulations also typically contain antacids such as
aluminium hydroxide or calcium carbonate to reduce gastric acidity. Because raft-forming
systems produce a layer on the top of gastric fluids, they are often used for gastro esophageal
reflux treatment as with liquid gaviscon (GlaxoSmithkline).
Figure 1.13: Schematic illustration of the barrier formed by a raft-forming system 
1.9.4. High density systems
Gastric contents have a density close to water (1.004 g /cm3). When the patient is
upright small  high-density pellets sink to the bottom of the stomach where  they become
entrapped in the folds of the antrum and withstand the peristaltic waves of the stomach wall.
A density close to 2.5 g/cm3 seems necessary for significant prolongation of gastric residence
time and barium sulphate, zinc oxide, iron powder, titanium dioxide are used as excipients.
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Figure 1.14: Illustration representing (A): the systems based on high density,
(B): the systems based on low density 
1.9.5. Low density systems
Gas-generating systems inevitably have a lag time before floating on the stomach
contents,  during  which  the  dosage  form may undergo  premature  evacuation  through  the
pyloric sphincter. Low-density systems (<1 g/cm3) with immediate buoyancy have therefore
been developed.  They are made of  low-density materials,  entrapping oil  or  air.  Most are
multiple unit systems, and are also called ‘‘microballoons’’ because of the low-density core.
Generally,  techniques  used  to  prepare  hollow  microspheres  involve  simple  solvent
evaporation  or  solvent  diffusion  methods.  Polycarbonate,  Eudragit  S,  cellulose  acetate,
calcium  alginate,  agar  and  low  methoxylated  pectin  are  commonly  used  as  polymers.
Buoyancy and drug release are dependent on quantity of polymer, the plasticizer–polymer
ratio and the solvent used.
Figure 1.15: (a) Microballoons and (b) Foam-particles 
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1.9.6. Expandable systems
A dosage form in the stomach will withstand gastric transit if it is bigger than the
pyloric sphincter. However, the dosage form must be small enough to be swallowed, and
must  not  cause  gastric  obstruction  either  singly  or  by  accumulation.  Thus,  three
configurations  are  required,  a  small  configuration  for  oral  intake,  an  expanded  gastro
retentive form and a final small form enabling evacuation following drug release.
Expandable systems are made of biodegradable polymer; the concept is to make a
carrier, such as a capsule, incorporating a compressed system, which extends in the stomach.
different geometric forms (tetrahedron, ring or planar membrane,4-lobed, disc or 4-limbed
cross form) of biodegradable polymer compressed within a capsule (Figure 1.16).
Figure 1.16: Different geometric forms of expandable systems 
1.9.7.Swellable System
Swellable  systems  are  also  retained  because  of  their  mechanical  properties.  The
swelling usually results from osmotic absorption of water. The dosage form is small enough
to be swallowed, and swells in gastric liquids, the bulk enable gastric retention and maintains
the stomach in a ‘fed’ state, suppressing housekeeper waves.
Mamajek and Moyer  patented drug reservoirs, surrounded by a swellable expanding
agent. Urquhart and Theeuwes  developed a system containing tiny pills, with a very high
23
swelling ratio enabling up to 50 fold volume increase. They were coated by wax to control
drug release and dispersed in a matrix of polymeric hydrogel (Figure 1.17).
Figure 1.17:Swellable systems, developed by (a)Mamajek and Moyer, and
(b) Urquhart and Theeuwes
1.9.8.Superporous hydrogels
            Although these are swellable systems, they differ sufficiently from the conventional
types to warrant separate classification with pore size ranging between 10 nm and 10 µm.
Absorption of water by conventional hydrogel is very slow process and several hours may be
needed to reach an equilibrium state during which premature evacuation of the dosage form
may occur.  Superporous hydrogel, average pore size > 100 µm, swell to equilibrium size
within  a  minute,  due  to  rapid  water  uptake  by  capillary  wetting  through  numerous
interconnected open pores. Moreover, they swell to a large size (swelling ratio 100 or more)
(Figure 1.18) and are intended to have sufficient mechanical strength to withstand pressure by
gastric  contractions.  This  is  achieved  by  a  co-  formulation  of  a  hydrophilic  particulate
material, Ac-Di-Sol (crosscarmellose sodium).
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Swellable expanding agent
Figure 1.18: On
the left, (a) superporous hydrogel in its dry and (b) water-swollen state. On the right,
schematic illustration of the transit of superporous hydrogels
1.9.9. Magnetic system
These  systems  appear  as  small  gastroretentive  capsules  containing  a  magnetic
material,  whose  elimination  from  the  stomach  is  prevented  by  the  interaction  with  a
sufficiently strong magnet applied to the body surface in the region of the stomach. Despite
numerous reports about successful tests, the real applicability of such systems is doubtful
because the desired results can be achieved only provided that the magnet position is selected
with very high precision. Probably, the development of new conveniently applied magnetic
field sources will improve this concept.
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                                                  LITERATURE REVIEW
Muralidhar Mama et  al8 2008: Developed  hydrodynamically balanced delivery system
ofClarithromycin (CLA) which, after oral administration should have the ability to prolong
gastric residence time with the desired in vitro release profile for the localized action in the
stomach,  in  the  treatment  of  Helicobacter  pylori  (H.pylori)  mediated  peptic  ulcer.  By
applying wet granulation technique floating tablets of  Clarithromycin were prepared.  The
proportion of  sodium bicarbonate  was  varied  to  get  the least  possible lag time,  also the
polymer part varied to get the desired release. In vivo radiographic studies were performed
with Barium sulphate loaded formulation to justify the increased gastric residence time of the
dosage form in the stomach, based on the floating principle. The formulation developed using
66.2% Clarithromycin, 12% HPMC K4polymer, 8% sodium bicarbonate gave floating lag
time less than 3 min with a floating time of 12 h, and an in vitro release profile very near to
the desired release. X-ray studies showed the enhanced gastric residence time of the tablet to
220±30 min. 
Patil UK et al9 2008: Developed Amlodipine besylate effervescent floating tablets in ten
different  formulations  (F1  to  F10)  by  employing  different  grades  of  polymers  and
effervescent  agents  such  as  sodium  bicarbonate  and  citric  acid.  The  formulations  were
evaluated for various physical parameter  buoyancy studies, dissolution parameters and drug
release mechanisms.F10formulation showed maximum floating time of 24 hours and gave
slow and maximum drug release of Amlodipinebesylate spread over 24 hours and whereas
Amlodipine besylate released from marketed tablet was rapid and maximum within 12 hours.
Mohamad abdul kalam azad et al10 2009 described the preparation and in vitro evaluation
of  gastro  retentive  floating  tablet  of  theophylline.  Two  hydrophilic  cellulose  derivatives,
Methocel K100M and Methocel K15MCR were evaluated for their gel forming and release
controlling  properties.  Sodium  bicarbonate  and  citric  acid  were  incorporated  as  gas
generating agents. The effects of soluble components (sodium bicarbonate and citric acid),
gel forming agents and amount variation of theophylline on drug release profile and floating
properties  were  investigated.  Tablets  were  prepared  by  direct  compression  technique.
Formulations were evaluated for in vitro buoyancy and drug release study was evaluated for
eight hours using USP XXII paddle-type dissolution apparatus using 0.1HCl as dissolution
medium. The release mechanisms were explored and explained with zero order, first order,
Higuchi and Korsmeyer equations. The release rate, extent and mechanisms were found to be
governed by polymer and floating agent content. The content of active ingredient was also a
vital factor in controlling drug release pattern. It was found that polymer content and amount
of floating agent significantly affected the mean.
Atul C. Badhan et al11 2009: Designed and optimized of sustained release gastro retentive
min imatrices of amoxicillin by using central composite design. Effect of amount of xanthan
gum, rate controlling polymers (HPMC K100M CR/PEO coagulant (1:1)), carbopol 974P,
and gas generating couple (sodium bicarbonate/citric acid (3:1)) was studied on dependent
(response) variables, i.e., buoyancy lag time, drug release at 1 h, time required for 95% drug
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release,  swelling  index,  and  strength.  Minimatrices  were  prepared  by  non  aqueous
granulation method using solution of PVP K30 in isopropyl alcohol.  All  the formulations
were found to contain 99.2% to 100.9% of amoxicillin per minimatrix. Optimum formulation
(Formulation number AGT09) containing high level  of  independent variables was having
buoyancy lag time of 7 min and drug release at 1 h was 32.5%. It required 9.39 h for 95%
drug release while  swelling index and bio adhesive strength were  341 and17.9 dyn/cm2,
respectively. This formulation was said to be optimum because it has minimum buoyancy lag
time, requires maximum time for 95% drug release, and has high bioadhesive capabilities. In
vitro  results  of  an  optimized  formulation  indicate  its  sustained  drug  release  and  gastric
retention capability, which may be very useful for effective treatment of H. pylori infection.
Sharad Shinde et  al12 2010:  Developed the floating matrix  tablets  SalbutamolSulphate.
Tablets were prepared by wet granulation method and were characterized using the official
method.  Hydroxypropyl methylcellulose was used as a release retardant material.  Sodium
bicarbonate and Citric acid was incorporated as a gas-generating agent. The effects of citric
acid  on  drug  release  profile,  floating  properties  and  matrix  integrity  of  tablet  were
investigated.  Addition  of  Citric  acid  caused  the  enhancement  in  drug  release  and
disintegration of tablet that was retarded by incorporation of stearic acid in the formulation.
Addition of high level of HPMC K100M didn’t significantly retard the burst effect and tablet
disintegration produced by citric acid but addition of stearic acid was necessary to retard the
same. Formulations were evaluated for in vitro drug release profile, swelling characteristics.
The similarity factor, dissolution kinetics, and  t50  were used as parameters for selection of
the best batch. 
ChandraShekar B et al13 2010: Designed and developed a gastro retentive drug delivery
system of Ketoconazole by direct compression technology. HPMC K100LV, HPMC K15M,
Ethyl Cellulose and effervescent sodium bicarbonate formed the floating tablet. The prepared
tablets  exhibited  satisfactory  physico-chemical  characteristics.  The  floating  tablets  were
evaluated for uniformity of weight, hardness, friability, drug content,  in vitro buoyancy and
dissolution  studies.  All  the  prepared  batches  showed good in  vitro  buoyancy.  The  tablet
swelled radically and axially during in vitro buoyancy studies. It was observed that the tablet
remained buoyant for 20-24 h. Final formulation released approximately89.21% drug in 24 h
in  vitro,  while  the  floating  lag time  was  not  more  than  35  Sec  and  the  tablet  remained
floatable throughout all studies. The tablets with HPMCK15M were found to float for longer
duration as compared with formulations containing HPMCK 4 M. The release Ketoconazole
was found to follow a mixed pattern of Korsmeyer-Peppas, Hixson-Crowell and zero order
release models. The optimized formulation was found to be buoyant for 24 h in stomach. The
drug release from the tablets was sufficiently sustained and non-Fickian transport of the drug
from tablets was confirmed.
P.  N.  Kendre,  R.K.Godge  et  al14 2010:   Developed  and  characterized  a  single  unit
controlled delivery system of Theophylline and was formulated as floating matrix tablet by
direct  compression  method using  gas  generating agent  (sodium bicarbonate)  and  various
viscosity grades of hydrophilic polymers (HPMCK15M, K4M; HPC and Carbapol 934P).
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Formulation was optimized on the basis of buoyancy and in vitro drug release profile. Also
tablets  were  tested  for  various  tests  like  hardness,  thickness,  weight  variation,  friability,
Swelling index and erosion index. The tablets swelled and eroded upon contact with release
medium (0.1 N HCl) at 37 0C. The release rate could efficiently be modified by varying the
matrix forming polymer, the use of polymer blends and the addition of water soluble or water
insoluble fillers (such as dicalcium phosphate, lactose or mannitol). Fitting the in-vitro drug
release data to Korsmeyer equation indicated that diffusion along with erosion could be the
mechanism of drug release.
  N.  B.  Santha  sheela  et  al152010:   Formulated  floating  sustained  release  tablets  of
Clarithromycin,  by  using  a  combination  of  hydrophilic  polymers  (different  grades  of
hydroxypropyl  methylcellulose),  Kollidon  SR  and  an  effervescent  substance  (sodium
bicarbonate).  The  formulations  were  evaluated to  study the  effect  of  sodium bicarbonate
concentration on the floating lag time, total duration of floating, in vitro dissolution release
profile  and the  effect  of  different  fillers  and  ethyl  cellulose concentration on the  release
profile of drug. It was found that among all the formulations, formulation F4 (HPMC K15M,
Avicel 102 pH and sodium bicarbonate) was found to be the optimum formulation as it had
good  swelling  property,  floating  time  and  drug  release.  The  drug  release  of  optimized
formulation was found to follow Zero order, Higuchi and Korsmeyer‐Peppas kinetic models.
R. Margret chandir et al16 2010:
                                       Designed and developed of hydro dynamically balanced tablet of
cefuroxime  axetil  to  enhance  the  bioavailability  and  therapeutic  efficacy  of  the  drug.
Cefuroxime axetil is classified as a second-generation cephalosporin antibiotic and beta lactum
antibiotics based on spectrum activity. Tablets are prepared by the direct compression technique
by using  HPMC K4M and  mannitol  as  polymers  along  with  sodium  bi  carbonate  as  gas
generating agent. Formulation were evaluated for in vitro buoyancy and drug release study
using up dissolution apparatus using 0.1N Hcl as a medium.The result indicate that floating
tablets of dissolution cefuroxime axetil containg 45mg HPMC K4M provides a better option
for control release action and improved bioavailability. 
Deepak Jain et al17 2010: Designed and optimized of Gastro retentive floating drug delivery
systems (GFDDS) of furosemide, an loop diuretic drug, with an oral bioavailability of only
50% (because of its poor absorption from lower gastrointestinal tract) using 3² full factorial
design.Hydroxypropyl methyl cellulose of different viscosity grades (K4M and K100M) was
used as the polymers and sodium bicarbonate as gas generating agent to reduce floating lag
time. The tablets were prepared by direct compression method. Estimation of furosemide in
the  prepared  tablet  formulations  was  carried  out  with  0.1N  HCl  and  measuring  the
absorbance  at  271  nm.The  prepared  formulations  were  further  evaluated  for  hardness,
friability,  weight  variation,  drug content  uniformity,  swelling index,  In-vitro  drug release
pattern,  short-term  stability  and  drug  excipient  interactions.  Majority  of  the  designed
formulations displayed nearly first order release kinetics, releasing more than 80% drug in 10
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hours  and  remained  buoyant  more  than  24  hours.  The  optimized  formulation  containing
furosemide  80  mg,HPMC (K4M) 100  mg and  sodium bicarbonate  30  mg has  displayed
almost  zero  order  release  kinetics  with  a  floating  lag  time  of  only  2.9  minutes.  This
formulation released more than 90% drug in 9 hours.  This study proves  that  GFDDS of
furosemide can be designed using HPMC K4M as matrix polymer, which provides nearly
zero order release kinetics and thus possienhancement of oral bioavailability of the drug.
I.  Sarath  Chandiran  et  al18 2010: Formulated  and  developed  salbutamol  sulphate  as  a
floating matrix tablets and control the drug release up to 24 h for administration as once daily
dose. Salbutamol Sulphate is a short acting bronchodilators which have short biological half
life about 2 - 4 h. Floating matrix tablets were formulated by using swelling polymer like
Methylcellulose,  Hydroxy  propyl  methyl  cellulose(K100M,  K4M)  with  different
concentration 25, 50, 75 % w/w of the polymer were used for the preparation of the floating
matrix tablets. The formulation variables like hardness, polymer concentrations, and shape of
the tablets were optimized to achieve the floating nature of the tablet in stomach for 24 h. In
addition stearic acidic included in this formulation to evaluate their release characteristics.
From this the hydrophilic floating matrix control the release up to 12 h with HPMC K100M
at75 % w/w of the polymer concentration. The formulations, which have stearicacid retards
the  drug  release  by  controlling  the  water  penetrations  in  to  the  floating  matrix  tablets,
sustained their drug release above 12 h. The floating matrix tablets with minimum hardness
of 5 kg/cm2 and round shaped tablets exhibited better
Jadav mayur et al19 2010: Formulated and developed floating tablets of Famotidine were
prepared by employing polymers like Guar gum and Xanthan gum by effervescent technique.
The  tablets  were  prepared  by  direct  compression  method.  The  polymers  were  used
individually as well as in combination to formulate floating tablets. Sodium bicarbonate was
incorporated  as  a  gas  generating  agent.  The  floating  tablets  were  evaluated  for
physicochemical  parameters such as hardness,  weight variation,  percent friability,  floating
properties (floating lag time, total floating time and matrix integrity), swelling studies, drug
content, stability study and In vitro drug release. The drug polymer interaction was studied by
DSC thermal analysis. The physicochemical parameters of formulated tablets were found to
be  within  normal  range.  The  floating  lag  time  of  all  the  formulations  was  within  the
prescribed  limit  (<10  minutes).  All  the  formulations  showed  good  matrix  integrity  and
retarded the release of drug for ten hours except the formulationsF1, F2 and F3. The release
pattern of Famotidine was fitted to different models based on coefficient of correlation(r).
The swelling studies of all the formulations showed that formulations containing combination
of Guar gum and Xanthan gum has higher swelling indices than individual Guar gum and
Xanthan gum.  Optimized formulation (F7) of Famotidine floating tablet  was found to be
stable for storage at 40°C/75% relative humidity for 3 months.
K.Karunakar et  al20 2011: Developed  Floating matrix  tablets  of  Lamivudine to prolong
gastric  residence  time and increase its  bioavailability.  Rapid gastrointestinal  transit  could
result in incomplete drug release from the drug delivery system above the absorption zone
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leading to diminished efficacy of the administered dose. The tablets were prepared by direct
compression technique, using polymers such as hydroxyl propyl methyl cellulose (HPMC
E15), Ethyl cellulose and Xanthan gum combination and other standard excipients. Sodium
bicarbonate  was  incorporated  as  a  gas-generating  agent.  The  effects  of  different
concentrations  of  HPMC,  EC  and  Xanthan  gum  on  drug  release  profile  and  floating
properties were investigated. Comparable release profiles between the commercial product
and  the  designed  system  were  obtained.  The  model  fitting  showed  that  the  optimized
formulation F2 formulations followed Korsmeyer and Peppas model,  which had a higher
value of correlation coefficient (r). While tablet hardness had little or no effect on the release
kinetics and was found to be a determining factor with regards to the buoyancy of the tablets. 
Pramod Patil  et  al21 2011: Developed  and  designed floating tablets  of  Ofloxacin which
prolong the gastric residence time after oral administration.  Ofloxacin is a fluoroquinolon
antibacterial agent which is highly effective against gram positive and gram negative bacteria.
Ofloxacin floating tablets were prepared by wet granulation method incorporating natural
polymer like guar gum, locust bean gum, either alone or in combination with HPMC K100M
as swelling polymers, with sodium bicarbonate as gas generating agent and were evaluated
for parameters such as Weight variation, Hardness, Friability, Drug content, Swelling index,
in vitro buoyancy study, in vitro drug release study. All the formulation showed compliance
with pharmacopieal standards. Based on the evaluation results, F3 and F6 formulations were
selected as the best formulations and were checked for stability as per ICH guidelines. These
results indicated that the selected formulations were stable. The drug release profile of the
best formulations was well controlled and uniform throughout the dissolution studies.  The
drug release of optimized formulation follows the Higuchi kinetic model, and the mechanism
is found to be non-Fickian/anomalous according to Korsmeyer–Peppas equation.
Gada et al  222011:  Designed and developed floating tablets by using direct  compression
technique using polymers like HPMCK4M, HPMCK15M and HPMCK100M for their gel
forming properties. The scientific and technological advancements have been made in the
research and development of controlled release oral drug delivery systems by overcoming
physiological adversities like short gastric residence times and unpredictable gastric emptying
times. Floating tablets are the systems which are retained in the stomach for a longer period
of time and thereby improve the bioavailability of drugs.
Mahalaxmi  Rathnanand  et  al23  2011:  Formulated  and  evaluated  (in  vitro)  of  floating
pulsatile  tablets  of  Nizatidine,  a  H2 receptor  antagonist,  which  conceptualizes  a  specific
technology, based on combining principles of both the floating and pulsatile principles to
deliver  a  programmed  dose  of  drug  from  the  developed  delivery system  anticipated  for
chronotherapy of excessively secreted gastric acid and for promoting healing of duodenal
ulcers.  Accordingly floating pulsatile  Nizatidine  tablets  were  developed in  three different
steps viz, preparation of immediate release drug containing core tablets,  time-lagged film
coating by a hydrophobic rupturable polymer, ethyl cellulose (EC), and compression coating
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of a buoyant layer using gel forming polymers like carbopol 934P, poly (ethylene oxide) and
sodium bicarbonate for the generation of carbon dioxide which is responsible for the floating
behaviour of the tablet on the gastric contents. The obtained tablets were evaluated for weight
variation, thickness, hardness, disintegration,  in vitro  floating properties (buoyancy studies)
and in vitro dissolution studies. Stability studies of the optimized formulation was carried out
as per ICH guidelines at 40 ± 2oC / 75 ±5% RH for one month and it was found to be stable.
Apparao et al24 2011: Developed and optimized a controlled- release floating tablet of highly
water soluble drug Nizatidine in an effort to increase its gastric retention time in the stomach.
The   tablets were prepared  by direct compression method  by  using  a  Hydroxypropyl
methylcellulose  (HPMC)  of  different  viscosity  grades,  Carboxymethyl  cellulose  Sodium
(NaCMC) were incorporated as retarding polymers. Sodium bicarbonate was incorporated as
effervescent agent.  Formulations were evaluated for weight variation,  thickness,  hardness,
percentage swelling, friability, and in vitro drug release, and floating lag time, total duration
of floating, dissolution efficacy and in vivo Mean Residence Time (MRT) in the stomach.
The formulation F6 with HPMC K 4M exhibited floating lag time of less than 1min and
floating time of more than 12 hrs. The drug release of the optimized formulation followed
Higuchi  kinetic  model (R2=0.9832) and the mechanism of  drug release was found to be
supercase II according to Krosmeyer-Peppas (n value is 0.60).  In vivo nature of tablet was
observed  at  different  time intervals  with  help  of  radiographic  pictures  in  healthy human
volunteers and MRT in the stomach was found to be 320 minutes.
Srinivas Pannala et al25  2011:  Developed and evaluated (in vitro)  Nizatidine immediate
release tablets.  The developed drug delivery system delivers  a programmed dose of drug
intended for excessively secreted gastric acid and for promoting healing of duodenal ulcers
thereby spontaneously delivering the drug when exposed into GIT for producing an anti-ulcer
effect.  Accordingly,  immediate  release  drug-containing  core  tablets  of  Nizatidine  were
prepared  by  wet  granulation  method.  The  obtained  tablets  were  evaluated  for  weight
variation, thickness, hardness, drug content, disintegration and  in vitro  dissolution studies.
Stability studies of the optimized formulation was carried out as per ICH guidelines at 40 ±
2oC / 75 ±5% RH for one month and it was found to be stable.
Kurnal  patel  M et  al26 2011: Formulated  and  developed  gastro  retentive  drug  delivery
system of Mebendazole. Chitosan and hydroxypropyl methyl cellulose of various viscosity
were used. Sodium bicarbonate was incorporated as a gas‐generating agent. The effects of
citric acid and steari acid on drug release profile and floating properties were investigated.
The addition of stearicacid reduces the drug dissolution due to its hydrophobic nature. The
specific study was carried out formulate such a dosage form that can neutralize the acidity
locally in the stomach. The granulation was formed by Fluidized bed processor in which top
spray technique was adopted for forming the granules.
Afasr c.shaikh et al27 2011: Formulated floating‐bio adhesive tablets of Tramadol by direct
compression  method  using  varying  amounts  Carbopol  971P  (CP)  and  Hydroxypropyl
methylcellulose (HPMC), along with other requisite excipients. In vitro drug release profile,
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floatation  characteristics  and  ex  vivo  bio  adhesive  strength  using  texture  analyzer  were
determined, and systematically optimized using a 32 central composite design (CCD). The
studies  indicated  successful  formulation  of  gastro  retentive  compressed  matrices  with
excellent  controlled release, mucoadhesion and hydrodynamic balance.  Comparison of the
dissolution profiles of the optimized formulation, with optimal composition of CP: HPMC:
80.0:125.0, with that of the marketed controlled release formulation. 
Sonia dhiman et al28 2012:   Developed controlled release floating type gastro retentive
tablets using Famotidine as a drug and HPMC K15M as a polymer. This targeted delivery of
the drug provides an effective and safe therapy with reduced dose and duration of therapy. A
floating controlled-release drug delivery system of Famotidine was developed by effervescent
approach  using  varying  concentrations  of  HPMC  K15M  and  sodium  bicarbonate.  The
matrices are fabricated using sodium bicarbonate (NaHCO3) and citric acid as gas formers so
that  upon  contact  with  gastric  fluid,  carbon  dioxide  is  liberated  that  is  entrapped  in  the
jellified hydrocolloids, which produces an upward motion of the dosage form and maintain its
buoyancy.
Ajay  Bagherwal  et  al  292010:   Formulated  and  developed  ciprofloxin  floating tablet  as
sustained release dosage form. HPMC and carbomer are the polymers, used as suspending
agent, viscosity increasing agent and tablet binder coating agents. In the present study, it was
aimed to formulate floating tablet of ciprofloxacin HCl with HPMC and carbomer in different
proportion (4%, 8% and  12%) by direct  compression techniques  using polymers  lactose,
magnesium Streate  and  talc  with sodium bicarbonate.  All  the  prepared  formulation were
found to complys with the official tests like precompression parameter like angle of repose
and  post  compression  parameters  like  Shape,  tablet  dimensions,  hardness,  friability  test,
weight variation test, floating test, content uniformity and in-vitro dissolution study. In-vitro
release  studies  were  carried  out  using  USP XXII  dissolution  test  apparatus.  The  mean
percentage  of  ciprofloxacin released  at  various  time intervals  was calculated  and  plotted
against  time.  The  mechanism of  drug  release  with  all  the  formulations  was  dominantly
diffusion and followed zero order kinetics. It was observed that the integrity of the drug is not
affected  by  formulation  procedure.  The  results  revealed  the  drug  polymer  ratio  showed
greater drug release than other formulations.
Ayesha naz et al30 2011:. Formulated and designed  Nizatidine floating tablets were prepared
by effervescence method using Sodium bicarbonate as a gas generating agent. The tablets
were formulated using direct compression technology by employing semi synthetic polymers
like various grades of HPMC such as HPMC K4M, K15M, K100M and natural polymers like
xanthan  gum  and  kondagogu  gum.  The  prepared  tablets  were  evaluated  for  various
physicochemical  parameters  such  drug-excipient  interaction  by  FTIR  and  DSC,flow
properties, hardness, weight variation, friability,  in vitro buoyancy (floating lag time, total
floating time),  swelling studies,  drug content and  in-vitro drug release.  The in vitro  drug
release pattern of  Nizatidine floating tablets  was fitted to  different  kinetic  models  which
showed highest regression for zero order kinetics with non fickian diffusion mechanism. Out
of  all  formulations  the  one  prepared  with  combination  of  HPMC K4M and  K15M was
optimised based on desired sustained release time (12hrs) and acceptable floating properties.
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The optimised formulation was evaluated for in vivo floating time in rabbits, which showed
the floating property in stomach up to 5 hours. The FTIR and DSC study revealed that there
is no drug-excipient interaction.
A.m.rao et al312011: Formulated and evaluated floating tablets of pioglitazone employing
calcium starch, a new modified starch in comparison to HPMC K15M, a synthetic cellulose
derivative.  Floating  tablets  of  pioglitazone  were  prepared  employing  calcium starch  and
HPMC, K15M as matrix formers, sodium bicarbonate as gas generating agent and bees wax
as floating enhancer and the tablets were evaluated for  in vitro buoyancy and drug release
characteristics.  Tablets  formulated  employing  calcium  starch  (50%),  sodium  bicarbonate
(10%) and bees wax (10%) exhibited floating over 36 hours with a floating lag time of 5 – 10
min. Pioglitazone  release from the floating tablets formulated was slow, spread over more
than 24 h and depended on the polymer used and its strength and concentration of sodium
bicarbonate in  the tablets.  Drug release was diffusion controlled and followed first  order
kinetics. Fickian diffusion was the drug release mechanism from all the tablets formulated.
Calcium starch gave slow, controlled and complete drug release in 24 h, Whereas HPMC;
K15M gave slow but incomplete drug release. Calcium starch was found to be a better matrix
former than HPMC for floating tablets.
Burpute S. S et al32 2011: Developed floating tablets of Nizatidine employing two different
grades of HPMC; these grades of HPMC were evaluated for their gel forming properties. The
other  polymer  carbopol  was  added  for  controlled  release  of  drug  from  the  formulation.
Sodium bicarbonate was incorporated as a gas-generating agent. The floating tablets were
evaluated for uniformity of content, hardness, friability, in vitro buoyancy, floating lag time,
dissolution studies and also for short term stability studies. The prepared tablets exhibited
satisfactory physico-chemical characteristics. All the prepared batches showed good in vitro
buoyancy. The tablet swelled radially and axially during in vitro buoyancy studies. 
Singh L. P et al33 2011::Developed a dosage form to prolong the release of drug from
dosage form and improve drug absorption in upper GIT and stomach and to optimize
using full factorial design. HPMC K100M (water swellable release retarding polymer),
gas generating agent NaHCO3 and citric acid were used to evaluate the release of the
drug. 32 factorial design was implemented at 25, 30 and 35 % concentration of the release
retarding polymer and 11.25, 13.75 and 16.25% concentration of gas generating agent to
correlate with the release pattern of the drug. Process variables like floating lag time,
cumulative  percent  release  and  swelling  index  were  investigated.  The results  showed
excellent  adaptability in absorption of the drug from narrow therapeutic window with
improved  gastric  retention.  Based  on  the  results,  formulation  of  dosage  form  with
optimum concentration of polymer and gas generating agent was possible to fulfil  the
desired need. 
Amul N. Mishra et al34  2011:  Formulated and evaluated of floating tablets of Ranitidine
Hydrochloride. Two different grades of hydroxy propyl methylcellulose namely Methocel K
100 M and Methocel K 15 M were used. It was observed that viscosity had a major influence
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on drug  release  from hydrophilic  matrices  as  well  as  on  floating  properties.  Dissolution
profiles were subjected various kinetic drug release equations and found that drug release
from hydrophilic matrices occurred via different mechanism following square root of time
profile  (Higuchi  equation).  Prepared  tablets  were  evaluated  for  Hardness  (Kg/cm2),
Thickness (MM), Average weight (mg), Weight variation, Hardness (Kg/cm2), Friability (%),
Drug content (mg/tab.), Floating Lag Time (Sec.), and total floating time (hr.). The granules
were characterized for Angle of repose, Bulk Density (gm/cm3), Tapped density (gm/cm3),
Carr’s index (%), and Hausners ratio, loss on drying and porosity. In vitro drug release study
of these tablets indicated controlled sustained release for Ranitidine HCL and 70 to 93% at
the end of 10m hrs. Hence, it is evident from this investigation that gas powered floating
matrix tablets could be promising delivery system for RHCL with sustained release action
and improved drug availability.  The formulations were found to be stable at  Rt/60o/75%
+5%RH for the period of three weeks.
A.  K  Pathak  et  al  352011:  Developed  a  bi-layer  tablet  of Metoprolol  tartrate  using 
disintegrant  starch  for the fast release layer and HPMC K grade polymers  for the sustaining
layer. In vitro dissolution studies were carried out in an Indian Pharmacopoeia dissolution
testing apparatus II (paddle method). The formulations gave an initial burst effect to provide
the loading dose of the drug followed by sustained release for 12 h from the sustaining layer
of matrix  embedded  tablets.  The  In-vitro release  study  of this  tablet  indicated  sustained
release for Metoprolol tartrate and followed zero order release and 95% drug in 24h in vitro
and it follow Fickian diffusion.
N. Damodharan et al36 2011: Developed Bi-layered floating tablets of Theophylline were
using wet granulation technique. The current study aims at formulation and evaluation of bi-
layered floating tablets of Theophylline. The floating tablets of theophylline were formulated
using polymers namely hydroxyl propyl methyl cellulose, sodium carboxy methyl cellulose,
methyl  cellulose  and  the  tablets  were  evaluated.  Two  layered  tablet  formulations  were
designed  with  an  immediately releasing  layer  consisting  of  Theophylline  with  lactose  as
diluents  and  sustained  release  layer  with  slow  releasing  swellable  matrix  consisting  of
theophylline  in  hydroxyl  propyl  methyl  cellulose,  sodium  carboxy methyl  cellulose  and
methyl  cellulose alone or  in  combination.  The formulations  were tested for  drug release,
floating  time,  floating  lag  time  and  drug  content.  Tablets  formulated  employing  a
combination of hydroxyl propyl methyl cellulose and methyl cellulose provide slow release
of Theophylline over a period of 9 hours and were found suitable for maintenance portion of
bi-layered floating tablets. Theophylline release from these tablets was diffusion controlled
and followed first order kinetics. The tablets exhibited good floating behavior in the stomach
for 9 hours.
Anitha Kakkerle et al372011: Developed and designed Floating matrix tablets of Alfuzosin
hydrochloride were to prolong gastric residence time.  Alfuzosin hydrochloride was chosen as
a model drug because it is poorly absorbed from the lower gastrointestinal tract. The tablets
were prepared by direct compression and melt granulation technique, using polymers such as
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hydroxy propyl  methyl  cellulose K15M, sodium carboxy methyl  cellulose,  compritol  888
ATO  and  either  alone  or  in  combination,  and  other  standard  excipients.  Tablets  were
evaluated  for  physical  characteristics  hardness,  %  friability,  floating  capacity,  weight
variation, content uniformity, in-vitro release characteristics for 12 hours and in-vivo gastic
retention time. In-vitro release mechanism was evaluated by linear regression analysis.  The
calculated regression coefficients value of higuchi and koresemayer (0.998, n value 0.520) for
optimized formulation F2  and  the  drug release  mechanism was  found to  be  non-ficikian
diffusion. No drug-polymer interaction was observed by Fourier Transform Infrared Spectra
Analysis.  In-vivo studies  showed  that  the  tablets  retained  in  stomach for  6hours.  It  was
concluded that, HPMC K15M alone retarded the drug release for highly water soluble drug
(Alfuzosin hydrochloride) for a period of 12 hours.
Anil G, Satyanarayana T et al38 2011:  Formulated and evaluated gastro retentive floating
tablets of venlafaxine hydrochloride, which releases the drug in a sustained manner over a
period of 12 hours. Three different viscosity grades Hydroxypropylmethylcellulose (HPMC)
namely K4M, K15M, and K100M were used for the preparation of tablets. The tablets were
prepared by direct compression and evaluated for tablet thickness, weight variation, tablet
hardness, friability, in vitro buoyancy test, in vitro drug release and Fourier transform infrared
(FT-IR) spectroscopy. Formulation F3 can be considered as an ideal or optimized formulation
for gastro retentive floating tablet of venlafaxine HCl. The optimized formulation showed
sufficiently sustained drug release and remained buoyant on the surface of the medium for
more than 12 hours. As the concentration of HPMC increases in the formulation the drug
release rate was found to be decreased. It can be concluded that floating drug delivery system
of  venlafaxine  HCl  can  be  successfully  formulated  as  an  approach  to  increase  gastric
residence time and there by improving its bioavailability.
Arun M, mahale et al39 2011: Developed a new drug delivery system for a water‐soluble
beta‐blocker drug, Metoprolol Succinate, utilizing both the concepts of adhesiveness and of
flotation, in order to obtain a unique drug delivery system which could remain in the stomach
for a much longer period of time. Floating‐Mucoadesive tablets of Metoprolol Succinate were
developed  to  prolong  its  release  and  improve  bioavailability  by  avoidance  of  first  pass
metabolism during the treatment of chronic hypertension. Tablets were prepared by direct
compression  using  directly  compressible  polymers  such  as  HPMC K4M,  HPMC K15M,
Sodium CMC and Carbopol 940P and were evaluated for buoyancy test, mucoadhesion force,
swelling study,  drug content,  Ex vivo  mucoadhesion strength and  in  vitro release profile.
Sodium bicarbonate was used for producing effervescent base for buoyancy of tablets. Result
indicated that release of Formulations best fitted square root kinetics. The swelling properties
were increased with increasing polymer concentration and contributed to the drug release
from the tablet  matrix.  No significant  change was observed in physical  appearance,  drug
content, floatability or in vitro dissolution pattern after storage at 45 °C / 75% RH for three
months.
Anilkumar Jet al40  2011: Formulated an oral floating tablet of cephalexin (CEF) using the
hydrophilic  polymer2  hydroxy  propyl  methyl  cellulose  (HPMC),  gas  generating  agent
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sodium bicarbonate  and  citric  acid.  A 3  factorial  design  was  applied  systematically;  the
amount of citric acid (X1) and amount of HPMC K100M (X2) were selected as independent
variables. The time required for 50% drug release (t ), percentage drug release at 12hr (Q )
and 50%  drug release at  6 hr (Q ) were selected as dependent variables.  The results  of
factorial design indicated that high level of HPMC K100M and citric acid favors preparation
of  floating  sustained  release  tablet  of  cephalexin.The  granules  were  prepared  by  wet
granulation method and evaluated for their granular properties. Tablets were compressed by
KBr press and evaluated with different parameters like diameter, thickness, average weight,
hardness, friability, drug content, in vitro buoyancy study, swelling characteristics, scanning
electron microscopy, kinetic release data. Hardness was found to being the range of 13 ± 0.23
to 13 ± 0.40 kg/cm, the percent friability was in the range of 0.0010 ± 0.02 to 0.0027 ± 0.01,
and  tablets  showed 99.63 ± 0.12 to  115.73 ± 0.13 of  the labelled  amount  of  cephalexin
indicating uniformity content. The tablets containing CEF released 72.28 to 99.461 % of drug
at the end of 12 hr by in vitro release.
Y and Zakir et al41 2011:  Formulate and evaluate hydro dynamically balanced controlled
drug delivery system of Glipizide.  This dosage form is  associated with many advantages
especially increased bioavailability and reduction in dosing frequency. The formulation was
designed adopting optimization technique, which helps in setting up experiments in such a
manner  that  the information is  obtained as  efficiently and precisely as possible.  Initially,
considering  buoyancy  as  the  main  criteria,  blank  tablets  were  compressed  for  different
formulae  with  various  polymers  like  Carbopol-940p,  HPMC,  Citric  acid  and  sodium  bi
carbonate. The formula selected for design had a combination of Glipizide, Carbopol-940p,
HPMC, Citric acid. The tablets were prepared by direct compression method and evaluated
for Glipizide content, in vitro release profile and buoyancy. The dissolution study was carried
out in simulated gastric fluid using USP dissolution test apparatus employing paddle stirrer.
Duration of buoyancy was observed simultaneously when the dissolution has carried out. The
variation  in  weight  was  within  the  range  of  ±3%  complying  with  pharmacopoeial
specifications  (±7.5%).  The  drug  content  varied  between  9.127±0.1317mg  and
9.923±0.0183mg in different formulations indicating content uniformity.. The in-vitro release
was found to be in the range of 50.28% to 99.65%. The Glipizide content in the formulation
varied  between91–100%.  The  optimized  formulation  F9  exhibited  responses  that  were
comparable with that of the predicted values of the design in optimization technique. This
indicates the suitability of the technique chosen for the present dosage form.
Madhusudan Rao Y et al42 2012: Developed gastro retentive formulation cefuroximeaxetil
with the  low  bioavailability  (30-40%)  and  short  biological  half  life  (1.5  hours)  oral
administration favours. Gastro retentive floating matrix tablets of Cefuroxime Axetil were
successfully prepared with hydrophilic polymers like HPMC K4M and HPMC K15M.From
the Preformulation studies for drug excipients compatibility it was observed that there was no
compatability problem with the excipients used in study. The drug release from most of the
formulations follows fickian diffusion. From vivo X-ray studies, it was clearly observed that
the floating tablets showed a gastric residence of nearby 6 hrs in fed state.
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3. AIM
 To design and formulate gastro retentive drug delivery system for Nizatidine.
OBJECTIVES.
  1. Development  of  effervescent  floating  matrix  tablets  of  Nizatidine  with  different
polymers.
2. To evaluate the physicochemical characteristics of all formulations and to carryout in
vitro drug release studies using USP type 2 apparatus.
3. To select the best formulation based on the above studies.
4.To carry out the stability studies to the best formulation.
. 
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4. PLAN OF WORK
In order to meet the objective the present work was planned in the following manner: 
 Preparation of calibration curve of Nizatidine in 0.1 N HCl (pH 1.2).
 Solubility study of Nizatidine in 0.1N HCl (pH 1.2).
 Stability study of Nizatidine in 0.1N HCl (pH 1.2).
 To determine the flow properties of the final blend.
 Determination of drug-excipient compatibility using FTIR and DSC studies.
 Formulation of Nizatidine floating tablets with HPMC K4M, Polyox WSR 1105. 
 Evaluation  of  Nizatidine  floating  tablets  for  weight  variation,  thickness,  hardness,
friability, drug content, floating lag time and total floating duration time.
 Theoretical release pattern.
 In vitro drug release studies of prepared floating tablets in 0.1 N HCl (pH 1.2) by
using  USP  dissolution  apparatus,  rotating  paddle  type  and  selection  of  best
formulation.
 Stability study of the best formulation.
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5. MATERIALS AND EQUIPMENT USED
Table. 5.1: Materials used in the study
Name of chemical Source
Nizatidine      VIVIMED  LABS  LIMITED
HPMC K4M      VIVIMED  LABS  LIMITED
Polyox WSR1105      VIVIMED  LABS  LIMITED
MCC (Avicel PH 102)      VIVIMED  LABS  LIMITED
Sodium bi carbonate      VIVIMED  LABS  LIMITED
Magnesium stearate      VIVIMED  LABS  LIMITED
Talc      VIVIMED  LABS  LIMITED
Conc. Hydrochloric acid      VIVIMED  LABS  LIMITED
.
Table. 5.2: Equipment used in the study
Equipment Model no. Manufacturer
Rotary tablet machine RDD3 Riddhi, Ahmedabad.
Digital weighing balance AUX 220 Shimadzu, Japan.
Pfizer hardness tester CMTT R/1342/98 Cadmach, Ahmedabad.
Friabilator (USP) EF2 Electro Lab, Mumbai.
Dissolution apparatus TDT 06P Electro Lab, Mumbai.
UV–Visible Spectrophotometer SL 159 Elico Pvt. Ltd., Hyderabad.
FTIR spectrophotometer BX I Perkin Elmer, USA.
Differential Scanning Calorimeter DSC 822 e/200 Mettler Toledo, Switzerland.
Glass ware Borosil & Schott Duran.
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5.1.1. DRUG-EXCIPIENT PROFILE
 5.1.1.1.DRUG PROFILE43
Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production,
and commonly used in the treatment of peptic ulcer disease (PUD) and Gastro Esophageal
Reflux Disease (GERD).
Nizatidine  is  considered  a  good  candidate  for  incorporation  in  a  gastro-retentive
dosage  form  because  this  delivery  system  promotes  local  delivery  of  the  histamine  H2-
receptor antagonist to the receptor of parietal cell wall. Local delivery increases the stomach
wall  receptor  site  bioavailability  of  the  histamine  H2-receptor  antagonist  to  reduce  acid
secretion.  The  increase  in  acid-secretion  reducing  capacity  is  described  as  being
advantageous in the treatment of ulcer patients. As its solubility decreases with increase in
pH,  it  would  be  more  beneficial  to  retain  the  drug  in  stomach (acidic  environment)  for
prolonged duration to achieve maximum absorption and receptor site bioavailability.
So gastro retentive drug delivery system is desirable to prolong the residence time of
the dosage form in the stomach until the drug is completely released from the system.
.Chemical name: N-(2-[(2-[(dimethyl amino) methyl] thiazol-4-yl) methylthio] ethyl)
-N-methyl-2-nitroethene-1,1-diamine.
Molecular formula: C12H21N5O2S2
Molecular weight   :  331.46 g/mol.
PHYSICAL PROPERTIES
Description: It is a white to off-white crystalline powder
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Solubility: Freely soluble in methanol.
Shows pH dependent solubility.
Water solubility (mg/ml): > 100, 46.1, 26.7 (pH 5, 7, 9),
i.e, highly soluble in 0.1N HCl (pH 1.2).
Partition co-efficient: 0.7
Melting range            : 130-134o C
PHARMACOKINETIC PARAMETERS
Bioavailability : >70%
Protein binding : 35%
Half-life : 1-2 hours
Cmax: 700 to 1,800 µg/L for a 150-mg dose and 1,400 to 3,600µg/L for a 300-mg dose.
Tmax : 1.5 hours
Volume of distribution: 0.8 to 1.5 L/kg.
DOSAGE AND ADMINISTRATION:
Active  duodenal  ulcer:  The  recommended  oral  dose  for  adults  is  300  mg once  daily  at
bedtime. An alternative dosage regimen is 150 mg twice daily.
Maintenance of healed duodenal ulcer: The recommended oral dose for adults is 150 mg once
daily at bedtime.
Gastro Esophageal Reflux Disease: The recommended oral dose in adults for the treatment of
erosions, ulcerations, and associated heartburn is 150 mg twice daily.
Active benign gastric ulcer: The recommended oral dosage is 300 mg given either as 150 mg
twice daily or 300 mg once daily at bedtime. Prior to treatment, care should be taken to
exclude the possibility of malignant gastric ulceration.
Pediatric Dosing  :
Erosive esophagitis: For pediatric patients 12 years or older, the dose is 150 mg b.i.d. (300
mg/d).
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Gastro Esophageal Reflux Disease: For pediatric patients 12 years or older, the dose is 150
mg b.i.d. (300 mg/day). The maximum daily dose for Nizatidine is 300 mg/day. The dosing
duration may be up to eight weeks.
DRUG CLASS AND MECHANISM
Nizatidine is a competitive, reversible inhibitor of  histamine at the histamine H2-receptors,
particularly those in the gastric parietal cells.
SIDE EFFECTS
Serious  reactions:  hepatitis,  thrombocytopenic  purpura,  exfoliative  dermatitis,  leukopenia,
pneumonia.
Common reactions: headache, rhinitis, abdominal pain, nausea and dizziness.
CONTRA INDICATIONS:
Nizatidine is contraindicated in patients with known hypersensitivity to the drug. Because
cross  sensitivity  in  this  class  of  compounds  has  been  observed,  H2-receptor  antagonists,
including Nizatidine, should not be administered to patients with a history of hypersensitivity
to other H2-receptor antagonists.
DRUG INTERACTIONS
Nizatidine can potentially interact with a few other medicines. Some of the medicines that
may lead to Nizatidine interactions include:
Aspirin,Atazanavir,Itraconazole, Ketoconazole.
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5.1.1.2. EXCIPIENT PROFILES44
5.1.1.2 (a)  HYDROXYPROPYLMETHYLCELLULOSE (HPMC)
Nonproprietary Names:
BP: Hypromellose
JP: Hypromellose
PhEur: Hypromellose
USP: Hypromellose
Synonyms:  Benecel  MHPC;  E464;  hydroxyl  propyl  methylcellulose;  HPMC;
hypromellosum;  methocel;  methylcellulose  propylene  glycol  ether;  methyl  hydroxyl
propylcellulose; metolose; MHPC; pharmacoat;tylopur; tylose MO.
Chemical Name:  Cellulose, 2-hydroxypropyl methyl ether.
Structural Formula:
Where R is H, CH3, or CH3 CH (OH) CH2
Physical and chemical properties:
Molecular weight : 10,000 – 15, 00,000
Color : White to creamy-white 
Nature : Fibrous or granular powder
Odor : Odorless
Taste : Tasteless
Density : 0.3-1.3 g/ml
Specific gravity : 1.26
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Solubility: Soluble in  cold water,  practically insoluble in chloroform,  ethanol  (95%) and
ether but soluble in mixture of ethanol and dichloromethane.
Viscosity: 4,000 mPas (HPMC K4M, 2% solution).
Melting point:  Browns at  190-200C, chars at  225-230°C, Glass transition temperature is
170-180°C.
Functional  category:  Bioadhesive  material,  coating  agent,  film-forming,  rate-controlling
polymer for sustained release, stabilizing    agent, suspending agent, tablet binder, viscosity-
increasing agent.
Applications:
 In  oral  product  HPMC is  primarily used  as  tablet  binder,  in  film  coating  and  as  an
extended release tablet matrix. Concentration between 2-5% w/w may be used as a binder
in either wet or dry granulation process. High viscosity grade may be used to retard the
release of water-soluble drug from a matrix.
 HPMC is widely used in oral and topical pharmaceutical formulation.
 Concentration of 0.45-1% w/w may be added as a thickening agent to vehicle for eye
drop and artificial tear solution.
 HPMC is used as an adhesive in plastic bandage and as a wetting agent for hard contact
lenses. It is widely used in cosmetics and food products. In addition, HPMC is used as an
emulsifier,  suspending agent and stabilizing agent in topical  gels and ointments.  As a
protective colloid, it can prevent droplets and particle from coalescing or agglomerating,
thus inhibiting the formation of sediments.
Stability  and storage: It  is  stable although it  is  slightly hygroscopic.  The bulk material
should be stored in an airtight container in a cool and dry place.
5.1.1.2 (b)  POLYETHYLENE OXIDE
Nonproprietary Names: USP-NF: Polyethylene Oxide.
Synonyms: Polyox; polyoxiante; polyoxirane; polyoxyethylene.
Chemical Name: Polyethylene oxide
Structural Formula: (CH2CH2O)n
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Physical and chemical properties:
Molecular weight : 9, 00,000
Color : White to off-white 
Nature             : Free-flowing powder
Odor : Slight ammoniacal odor
Density (true) : 1.3 g/mL
Solubility: Soluble in water and a number of common organic solvents such as acetonitrile,
chloroform,  and  methylene  chloride.  It  is  insoluble  in  aliphatic  hydrocarbons,  ethylene
glycol, and most alcohols.
Viscosity: 8,800 – 17 600 mPas (5% solution).
Melting point: 65 – 70oC.
Functional category: Mucoadhesive; coating agent; tablet binder; thickening agent.
Applications:
 Polyethylene oxide can be used as a tablet binder at concentrations of 5–85%. The higher
molecular  weight  grades  provide  delayed  drug  release  via  the  hydrophilic  matrix
approach.
 Excellent mucoadhesive polymer.
 Low levels of polyethylene oxide are effective thickeners, although alcohol is  usually
added to water based formulations to provide improved viscosity stability.
 Polyethylene oxide films demonstrate good lubricity when wet. This property has been
utilized in the development of coatings for medical devices.
 Polyethylene oxide can be radially cross-linked in solution to produce a hydrogel that can
be used in wound care applications.
Stability and storage: Store in tightly sealed containers in a cool, dry place. Avoid exposure
to high temperatures since this can result in reduction in viscosity.
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5.  2.1.1.2 (c)  SODIUM BICARBONATE
Non-proprietary names:
BP: Sodium Bicarbonate
JP: Sodium Bicarbonate
PhEur: Sodium Hydrogen Carbonate
USP: Sodium Bicarbonate
Synonyms:  Baking soda, E-500, monosodium carbonate,  Effer-soda, Sal de Vichy, sodium
hydrogen carbonate, sodium acid carbonate.
Chemical Name:  Carbonic acid monosodium salt.
Structural Formula:  NaHCO3
Physical and chemical properties:
Molecular weight: 84.01
Color : White  
Nature : Crystalline powder
Odor : Odorless
Taste : Saline/slightly alkaline
Density : 0.869-2.173 g/cm3
Solubility: Soluble in water, practically insoluble in ethanol (95%) and ether.
Osmolarity: 1.39% w/v aqueous solution is iso-osmotic with serum.
Melting point: 270 °C (with decomposition).
Category: Alkalizing agent, therapeutic agent.
Applications:
 Used in  pharmaceutical  formulation as  a  source of  carbon dioxide in effervescent
tablets and granules.
 Used  to  produce  or  maintain  an  alkaline  pH  in  a  preparation,  like  solution  of
erythromycin, lidocaine, and niacin etc.
 Used to produce a sodium salt of the active ingredient that has enhanced solubility.
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 Used as a freeze-drying stabilizer and in toothpaste.
 Used as a gas  forming agent in alginate raft  system and in floating drug delivery
system.
 Used as component of oral rehydration salts and isotonic injection/infusion.
Stability and storage:  Sodium bicarbonate is stable in dry air but slowly decomposed in
moist air and should therefore be stored in well-closed container in a cool & dry place.
5.1.1.2 (d)  MICROCRYSTALLINE CELLULOSE
Non-proprietary names:
BP: Microcrystalline Cellulose
JP: Microcrystalline Cellulose
PhEur: Cellulose, Microcrystalline
USP-NF: Microcrystalline Cellulose
Applications:   MCC is widely used in pharmaceuticals, primarily as a binder/diluents in oral
tablet and capsule formulation where it is used in both wet and dry granulation processes. In
addition  to  its  use  as  a  binder/diluents,  MCC  also  has  some  lubricant  and  disintegrant
properties that make it useful in tableting. 
Description: Microcrystalline cellulose (MCC) is purified, partially depolymerized cellulose
that occurs as a white, odourless, tasteless, crystalline powder composed of porous particles. 
Solubility:  practically insoluble in dilute acids and alkalis, organic solvents and water.
Incompatibilities: Microcrystalline cellulose is incompatible with strong oxidizing agents.
5.1.1.2 (e)  MAGNESIUM STEARATE
Nonproprietary names    :
BP: Magnesium Stearate
JP: Magnesium Stearate
PhEur: Magnesium Stearate
Empirical formula: C36 H70 Mg O4
Functional category: Tablet and capsule lubricant.
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Applications: It  is  widely  used  in  cosmetics,  food  and  pharmaceutical  formulations.
Primarily used  in  capsule  and tablet  manufacture at  a  concentration in  between  0.25%to
5.0%.
Description: It is a very fine, light white, precipitated or milled, impalpable powder of low
bulk density,  having a faint  odor of stearic acid and a characteristic taste. The powder is
greasy to the touch and readily adheres to the skin.
Solubility: Practically insoluble in ethanol (95%), ether and water. Slightly soluble in warm
benzene and warm ethanol (95%).
Incompatibilities: Incompatible with acids, alkalis, and iron salts.
5.1.1.2 (f)  TALC
Nonproprietary names:
BP: Purified Talc
JP: Talc
PhEur: Talc
USP: Talc
Empirical formula: Mg6 (Si2 O5)4 (OH)4
Functional category: Anticaking agent, glidant, tablet and capsule diluent; tablet and capsule
lubricant.
Application in pharmaceutical technology: It is generally used in oral solid dosage forms
as a lubricant and diluents. It is also used in topical preparations as a dusting powder.
                                Use                                         Concentration (%)
o Dusting powder               90-99
o Glidant and tablet lubricant                       1-10
o Tablet and capsule diluent        5-30
Description:  Talc  is  very  fine,  white  to  grayish-white  colored,  odorless,  impalpable,
unctuous, crystalline powder. It adheres readily to the skin, is soft to the touch, and free from
grittiness.
Solubility: Practically insoluble in dilute acids and alkalis, organic solvents and water.
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Incompatibilities: Incompatible with quaternary ammonium compounds.
5.1.1.2(g) CITRIC ACD:
Synonyms: Citro; E 330;F 4020, CheMfill, Aciletten
Empirical formula: C6H8O7
Molecular formula: 192.12
        
Citric acid
Chemical Properties: White crystalline powder
Description: Colorless, odorless crystals with an acid taste. Denser than water.
Density : 1.542
Storage temp. : Store at RT.
Solubility: H2O:1 M, clear, colorless.
Water Solubility: 750 g/L (20 ºC)
Sensitive :Hygroscopic
Stability: Stable. Incompatible with bases, strong oxidizing agents, reducing agents.
Citric acid is a very useful and effective preservative, obtained from naturally occurring 
organic acids. It exists in many different fruits and vegetables, but is especially concentrated 
in lemons and limes. Although it is also produced in refineries by using cane sugar, molasses,
and dextrose, the citric acid stocked by Mountain Rose Herbs comes from the fermentation of
crude fruit sugars. Citric acid is used extensively in the food, beverage, cosmetic, and 
pharmaceutical industries. It has been recognized as safe by all major national and 
international food regulatory agencies, and is also approved by the US Food and Drug 
Administration and in Europe for use in food. Citric acid is used for many different reasons, 
including (but not limited to): 
• Antioxidant and preservative properties
• prevents rancidity and bacteria growth
• Astringency and Acidity
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• Used in sourdough bread for an extra tart taste (known as "sour salt" among bakers)
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5.2. EXPERIMENTAL PROCEDURES:
5.2.1. PREFORMULATION STUDIES45
5.2.1.1 Solubility study of Nizatidine in 0.1 N HCl
Excess  amount  of  Nizatidine  was  placed  in  0.1  N HCl  in  order  to  determine  its
solubility. The sample was shaken for 24 hrs at 37 °C in a horizontal shaker. The supernatant
was  filtered  and  the  filtrate  was  diluted  with  the  0.1  Hcl  and  assayed  by  UV-Visible
spectrophotometer at λmax314 nm.
5.2.1.2. Stability study of Nizatidine in 0.1 N HCl
 Some amount  of  Nizatidine  was  placed  in  0.1  N HCl  in  order  to  determine  its
stability. In predetermined time points like 0.5, 1, 2, 3, 4, 6, 8, 10 & 24 hours samples were
assayed by UV-Visible spectrophotometer at λmax314 nm.
5.2.1.3. DRUG EXCIPIENTS COMPATIBILITY STUDIES
 5.2.1.3(a) PHYSICAL INCOMPATABILITY
  
S.NO
             INGREDIENTS
DRUGEXIPIEN
T
RATIO
     
         OBSERVATION
        
INTIAL
40±2C/75%R
H
   AFTER1-
MONTH        
      1
                   
   Nizatidine                                     _
 
Off white 
crystalline
powder
 
No
characteristic
change
       2
DRUG  +
    HPMC
            
            1:1 Off white 
crystalline
powder
No
characteristic
change
       3
    
DRUG+POLYOX  WSR 1105             1:1
Off white 
crystalline
powder
No
characteristic
change
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       4
DRUG+NAHCO3             1:1 Off white 
crystalline
powder
No
characteristic
change
       5 DRUG+CITRICACID
            
            1:1 Off white 
crystalline
powder
Slightly 
colour 
changes to 
brown.
       6
DRUG+TALC             1:1 Off white 
crystalline
powder
No
characteristic
change
       7 DRUG+MCC             1:1 Off white 
crystalline
powder
No
characteristic
change
       8 DRUG+MAGNESIUMSTERATE
  
1:1 Off white 
crystalline
powder
No
characteristic
change
5.2.1.3(b) CHEMICAL INCOMPATABILITY46
a) Fourier Transform Infrared (FTIR) Spectroscopy
The Fourier transform infrared (FTIR) spectra of samples were obtained using FTIR
spectrophotometer. Pure drug, individual polymers and their mixtures were subjected to FTIR
study. About 2–3 mg of sample was mixed with dried potassium bromide of equal weight and
compressed to form a KBr disk. The samples were scanned from 400 to 4000 cm−1.
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b) Differential Scanning Calorimetry (DSC)
Differential Scanning Calorimetry (DSC) experiments were carried out to find out the
presence of any interaction among drug and the excipients. Pure drug, individual polymers
and their mixtures were subjected to the study. 5-15 mg of sample to be analysed was taken in
the pierced DSC aluminium pan and scanned in the temperature range of 50–250 °C. The
heating rate was 10°C/min; nitrogen served as purged gas and the system was cooled down
by liquid nitrogen. The differential thermal analyser was used for this purpose.
5.2.1.2. EVALUATION OF FINAL BLEND47
The Final blend of all formulations was evaluated for Bulk density, Tapped density,
Compressibility Index, Hausner ratio and Angle of repose.
a) Bulk Density
About 20gms of material was passed through a sieve no. 40 to break up agglomerates
and introduced into a dry 50mL cylinder.  Without compacting,  the powder was carefully
leveled and the unsettled apparent volume, Vo, was read. The bulk density was calculated, in
grams per mL, using the following formula:
Bulk density = M / Vo
Where, M = Total mass of the material
b) Tapped Density 
After carrying out the procedure as given in the measurement of  bulk density the
cylinder  containing  the  sample  was  tapped  using  a  mechanical  tapped  density  tester
(Electrolab). The cylinder was tapped until no change in volume and then tapped volume Vf,
was measured to the nearest graduated unit. The tapped density was calculated, in grams per
mL, using the formula:
Tapped density = M / Vf
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c) Measures of Powder Compressibility
The Compressibility index  and Hausner  ratio  are measures  of the propensity of  a
powder to be compressed.
(1)Compressibility index =   [(Vo-Vf) / Vo] X 100
             (2) Hausner ratio = Vo/ Vf
Where, Vo = Bulk volume
Vf = Tapped volume
                                  Table 5.4:Scale of flowability
Compressibility index
(%)
Flow ability Hausner ratio
11-15 Good 1.12-1.18
16-20 Fair 1.19-1.25
21-25 Passable 1.26-1.34
26-31 Poor 1.35-1.45
32-37 Very poor 1.46-1.59
>38 Very, Very poor >1.60
d) Angle of Repose48
The fixed funnel method was employed to measure the angle of repose. The funnel
height was maintained approximately 2 - 4 cm from the top of the powder pile in order to
minimize the impact of falling powder on the tip of the cone. The blend was carefully pored
through the funnel. The height  ‘h’ of the pile from base and radius  ‘r’ of the base of the
conical  pile  was  measured.  The  angle  of  repose,  α,  was  calculated  using  the  following
formula:α = tan-1
Table 5.5: Flow properties and corresponding angles of repose
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5.2.3.
ANALYTICAL METHODS
5.2.3.1. Calibration curve of Nizatidine in 0.1 N HCl49
Calibration curve of Nizatidine was plotted in 0.1 N HCl (pH 1.2)
              An accurately weighed amount of 100 mg of Nizatidine was transferred separately
into 100 ml volumetric flask containing 0.1N HCl and then the volume was made up to the
mark with 0.1N HCl. From this, necessary dilutions were made to give concentration ranging
from  0-275  µg/ml  solutions.  The  absorbances  of  these  solutions  were  recorded  at  λmax
(314nm) of the drug and plotted graphically to give the standard graph of Nizatidine.
5.2.4. PREPARATION OF NIZATIDINE FLOATING TABLETS
Technology Applied: Direct compression.
The key ingredients included in the formulations are: 
    HPMC Hydrophilic polymer  Modify drug release pattern
    Polyox WSR 1105 Mucoadhesive agent
    Sodium bicarbonate  Effervescent agent
    Avicel  PH 102(MCC)  Filler
     Talc  Anti adherent
     Magnesium sterate   Lubricant
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Angle of repose (degrees) Powder flow
25-30 Excellent
31-35 Good
36-40 Fair - aid is not needed
41-45 Passable - may hang up
46 – 55 Poor - must agitate, vibrate
56 – 65 Very poor
Preparation procedure: Accurately weighed quantities of polymer and MCC were taken in a
mortar and mixed geometrically. To this required quantity of Nizatidine was added and mixed
slightly with pestle. Accurately weighed quantity of sodium bicarbonate was taken separately
in a mortar and powdered with pestle.  The powder was passed through sieve no. 40 and
mixed with the drug blend which was also passed through sieve no. 40. The whole mixture
was collected in a plastic bag and mixed for 3 minutes. To this talc was added and mixed for
2  minutes,  later  magnesium  stearate  was  added  and  mixed  for  3  minutes.  The  mixture
equivalent to 500 mg was compressed into tablets with 10 mm round concave punches at a
hardness of 6 kg/cm2. 
.Table  5.6:  Composition  of  Nizatidine  floating  tablets  containing  HPMC
K4M&POLYOX WSR1105 
Ingredients
                            
                  Formulations(Weight in mg)
F1 F2 F3 F4 F5 F6 F7
Nizatidine 270 270 270 270 270 270 270
HPMC K4M 100 75 80 - - - -
Polyox WSR 1105 - - - 80 100 110 115
Sodium bicarbonate 50 60 60 60 60 60 60
Citric acid anhydrous 10 - - - - - -
Avicel PH 102 56 81 76 76 56 46 41
Talc 7 7 7 7 7 7 7
Magnesium stearate 7 7 7 7 7 7 7
Total tablet weight 500 500 500 500 500 500 500
5.2.5. EVALUATION OF NIZATIDINE FLOATING TABLETS50
 Weight variation
 Thickness
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 Hardness
 Friability
 Floating lag time
 Total floating time
 Water absorption study
 Drug content
 In vitro drug release
a) Weight Variation test:
Twenty  (20)  tablets  from each  batch  were  individually  weighed  in  grams  on  an
analytical  balance.  The average weight and standard deviation were calculated,  individual
weight of each tablet was also calculated using the same and compared with average weight.
Table 5.7: Weight variation tolerances for uncoated tablets
Maximum % of
weight
difference allowed
Average weight of tablets(mg)
USP IP
10 <130 <80
7.5 130 – 324 80-250
5 >324 >250
b) Thickness test:
The thickness in millimeters (mm) was measured individually for 10 pre weighed
tablets  by  using  Vernier  Calipers.  The  average  thickness  and  standard  deviation  were
reported.
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c) Hardness test:
Tablet hardness was measured using a Pfizer hardness tester. The crushing strength of
the 10 tablets with known weight and thickness of each was recorded in kg/cm2 and the
average hardness, and the standard deviation was reported.
d) Friability test:
Twenty (20) tablets were selected from each batch and weighed. Each group of tablets
was rotated at 25 rpm for 4 minutes (100 rotations) in the Roche friabilator. The tablets were
then dedusted and re-weighed to determine the loss in weight. Friability was then calculated
as per weight loss from the original tablets.
e) In vitro buoyancy studies:
The in vitro buoyancy was determined by floating lag time. The tablets were placed in
a 100 mL beaker containing 0.1N hydrochloric acid. The time required for the tablet to rise to
the surface and to float was determined as floating lag time. The duration of time for which
the dosage form constantly remained on the surface of medium was determined as the total
floating time.
f) Drug Content:
Twenty tablets were taken, powdered and the powder equivalent to one dose each was
transferred to a 100 mL volumetric flask and 0.1N HCl was added. The volume was then
made up to the mark with 0.1N HCl.  The solution was filtered and diluted suitably and drug
content in the samples was estimated using UV-Visible spectrophotometer at λmax314 nm.
g) In vitro drug release studie51:
The in vitro drug release study was performed for all the tablets using USP Type II
dissolution apparatus under the following conditions.
Dissolution test parameters:
Medium : 900 mL of 0.1 N HCl
Rotation speed  : 50 rpm
Temperature : 37 ± 0.5ºCs
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Sampling volume : 5 mL
Sampling time : 0.5, 1, 2, 3, 4, 6, 8, 10 hours
At predetermined time intervals samples (5 mL) were collected and replenished with
same volume of fresh medium. The drug content in the samples was estimated using UV-
Visible spectrophotometer at λmax314 nm.
5.2.6. STABILITY STUDIES52
The purpose of stability testing is to provide evidence on how the quality of a drug
substance or drug product varies with time under the influence of a variety of environmental
factors, such as temperature, humidity etc.
Design Plan:
The product is subjected to short term studies at 400C±20C/75%±5%RH for 3 months.
6. THEORETICAL DOSE CALCULATION53
The objective of this calculation was to arrive at the theoretical amount of drug that
must be present in the floating drug delivery system, being administered once a day and
capable of acting up to 12 hours.
The total dose of Nizatidine was calculated with available pharmacokinetic data. As
per the zero-order release principle, the rate of delivery must be independent of the amount of
drug remaining in the dosage form and constant over time. The release from the dosage form
with zero-order kinetics is shown by the equation.
Kr0 = Rate in = Rate out = Ke × Cd × Vd= Ke× DL
Where Kr0 is the zero-order rate constant for drug release (amount per time),
Ke is the first-order rate constant of overall drug elimination (per hour),
Cd is the desired drug level in the body (amount per volume),
Vdis the volume in which the drug is distributed.
And DL is the loading dose
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The loading dose is required to give initial rapid burst of dose so as to attain therapeutic
range immediately after dosing. 
 Loading dose (DL) = CSS Avg × Vd / F
Where, CSS Avg is the average steady-state plasma level,
And F is the fraction of dose absorbed.
 Maintenance dose (DM) = Kr0 × H
Where, H = Total desired time for sustained action in hours,
 Total Dose = DL + DM
Calculation  of  the  Loading  and  Maintenance  Dose  (Theoretical  Release)  Profile  of
Nizatidine: 
Loading dose (DL) = CSS Avg × Vd / F= 610 × 60 / 0.7 = 52,285 = 52 mg.
Ke =0.693/t1/2 = 0.693/1.5 = 0.462 h−1
Drug availability rate (Rate of drug input) = Kr0 = Ke× DL = 0.462 × 52 = 24 mg.
Maintenance dose (DM) = Kr0 × H = 24 × 12 = 288 mg.
If the maintenance dose begins the release of the drug at the time of dosing, it will add
to that which is provided by the initial dose, thus increasing the initial drug level. In this case,
a correction factor is needed to account for the added drug from the maintenance dose. This
correction factor is the amount of drug provided during the period from 0 to the time of
the peak drug level. Nizatidine reaches peak drug level in 1 hour.
Thus, corrected loading dose DL (corrected) = 52 – 24 = 28 mg.
Therefore, the total dose required is = DL (corrected) + DM= 28 + 288 = 316 mg.
Table 6.1: Theoretical release profile of Nizatidine
Time (hours) Release (mg) Cumulative % release
1 52 19.25
2 76 28.14
3 100 37.03
4 124 45.92
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6 172 63.7
8 220 81.48
10 268 100
12 316
Nizatidine daily dose is 300 mg, so that we should calculate the dose below that i.e.
268 mg up to 10 hours. The total dose of Nizatidine rounded off to 270 mg (with 28 mg
loading dose and 242 mg maintenance dose) for 10 hours period and used in the design of the
floating tablets of Nizatidine.
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7. RESULTS AND DISCUSSION
7.1. CALIBRATION CURVE OF NIZATIDINE
Different  concentrations  of  Nizatidine  were  prepared  in  0.1  N HCl  (pH 1.2)  and
absorbance values at λmax(314 nm) were noted. The calibration curve showed good linearity
with R2 value 0.9994.
Table 7.1: Absorbance of Nizatidine with different concentrations
at λmax (314 nm) in 0.1 N HCl
Concentration (µg/ml) Absorbance 
0 0
20 0.073
40 0.143
60 0.213
80 0.284
100 0.339
125 0.441
150 0.531
175 0.601
200 0.704
225 0.806
250 0.870
275 0.972
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Figure 7.1: Calibration curve of Nizatidine in 0.1N HCl at 314 nm
7.2.1. SOLUBILITY OF NIZATIDINE
Nizatidine is highly soluble in 0.1 N HCl, having quantitative solubility 112.9 mg/mL.
7.2.2.. STABILITY OF NIZATIDINE IN 0.1 HCL
This  study was  done as  per  the  method described  in  section  2.2.2.3.  Absorbance
values atλmax314 nm at different time points were tabulated.
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Table7.2: Absorbance of Nizatidine at different time points
Time (hours)
Absorbance atλmax314 nm
Average1 2 3
0 0.992 0.995 0.990 0.992
0.5 0.993 0.994 0.991 0.993
1 0.992 0.993 0.990 0.992
2 0.993 0.994 0.992 0.993
3 0.991 0.992 0.990 0.991
4 0.994 0.993 0.989 0.992
6 0.990 0.991 0.988 0.990
8 0.992 0.992 0.989 0.991
10 0.991 0.990 0.987 0.989
24 0.990 0.991 0.988 0.990
Table 7.2 showed that there was no change in the absorbance of Nizatidine at different
time points. This implied that Nizatidine is highly stable in 0.1 N HCl, for 24 hours.
7.2.3. DRUG-EXCIPIENT COMPATIBILITY STUDIES
7.2.3.1. PHYSICAL INCOMPATABILITY
                              There is no interaction between drug and exipients except citric acid.
7.2.3.2CHEMICAL INCOMPATABILITY
7.2.3.2.1. Fourier Transform Infrared (FTIR) Spectroscopy
Potential chemical interaction between drug and polymer may change the therapeutic
efficacy of the drug. To investigate the possibility of chemical interaction between drug and
excipients, samples were analyzed over the range 400–4000 cm−1 .
Table 7.3: Infra-Red band assignments for Nizatidine 
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Wave number (cm-1) Groups
3280,3210 NH stretch: 2 groups
3107 CH stretch in NO2-CH-
3094 CH stretch in thiazole ring
2945,2860, 2829,2784 CH stretch in NCH3, CH2CH2
1622 C=C, conjugated with NO2
1587 Asymmetric NO2 stretch, conjugated with C-C; thiazole 
ring, weak contribution
1521 Thiazole ring
1470,1458, 1435,1422 CH deformation in NCH3, CH2; CN stretch
1377,1359
Thiazole ring for one frequency is symmetric NO2,
H-bonded, conjugated.
Figure 7.2: Comparison of FT-IR spectra of pure Nizatidine (a), HPMC K4M &
Nizatidine mixture (1:1) immediately after preparation (b) and after one month
preservation at room temperature (f)
  The figure 7.2 suggested that there was compatibility between Nizatidine & HPMC K4M
because  FTIR  spectra  of  Nizatidine  &  HPMC  K4M  mixture  (1:1)  displayed  all  the
characteristic bands of drug, without any significant spectral shift.
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Figure 7.3: Comparison of FT-IR spectra of pure Nizatidine (a), Polyox WSR 1105 &
Nizatidine mixture (1:1) immediately after preparation (c) and after one month
preservation at room temperature (g)
          The figure 7.3 suggested that there was compatibility between Nizatidine & Polyox
WSR 1105 because FT-IR spectra of Nizatidine & Polyox WSR 1105 mixture (1:1) displayed
all the characteristic bands of drug, without any significant spectral shift.
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Figure 7.4: Comparison of FT-IR spectra of pure Nizatidine (a), citric acid anhydrous &
Nizatidine mixture (1:1) immediately after preparation (d) and after one month
preservation at room temperature (h)
The figure 7.4 suggested that there was incompatibility between Nizatidine & citric
acid because FTIR spectra of Nizatidine & citric acid mixture (1:1) (figure 4.5 (d)) which was
immediately analyzed after preparation showed extra peak at 1700 - 1800 cm-1(shown by
arrow)  other  than characteristic  bands of  drug.  FT-IR spectra of  Nizatidine & citric  acid
mixture (1:1) (figure 7.4 (h)) which was preserved one month and analyzed, showed entirely
different peaks which was lacking characteristic bands of drug.
7.2.3.2.2 Differential Scanning Calorimetry (DSC)
The thermal properties  of the drug and the mixture of  drug and excipients are of
important interest since this can help to assess the interaction among different components of
the  formulations.  The  DSC  curve  of  pure  Nizatidine  (NIZ-1)  showed  a  single  sharp
endothermic peak at 136.32°C (−130.50 J/g) corresponding to its melting point (130–134°C)
being started at 132°C and ended at 138°C. 
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Figure 7.5: DSC curves of pure drug Nizatidine (NIZ-1), pure polymer HPMC K4M
(NIZ-5) and 1:1 mixture of Nizatidine & HPMC K4M (NIZ-7)
The figure 7.5 suggested that 1:1 mixture of Nizatidine & HPMC K4M (NIZ-7) is
having  an  endothermic  peak  of  drug  at  139.79°C which  was  well  preserved  with  slight
changes in terms of broadening or shifting towards the higher temperature.
.
Figure7.6: DSC curves of Nizatidine pure drug (NIZ-1), pure polymer Polyox WSR 1105
(NIZ-6) and 1:1 mixture of Nizatidine & Polyox WSR 1105 (NIZ-8)
64
Thus, it was concluded that the drug is compatible with HPMC K4M, Polyox WSR
1105 used in the formulation.
Figure 7.7: DSC curves of Nizatidine pure drug (NIZ-1), pure citric acid anhydrous
(NIZ-2), 1:1 mixture of Nizatidine & citric acid immediately after preparation (NIZ-
3)7and after one month preservation at room temp. (NIZ-4)
The figure 7.7 suggested that citric acid anhydrous (NIZ-2) showed a single sharp
endothermic  peak  at  162.76°C  corresponding  to  its  melting  point  (MP  153°C).
Decomposition of  the  organic  acid  started  immediately after  the  melting event  since the
signal did not return to the baseline level, but continued its downward shift. This thermal
instability of citric acid anhydrous at  temperatures above its melting point  was consistent
with the TGA findings and was detectable in all the physical blends as a broad peak around
190oC exhibiting concentration-dependent intensity. In NIZ-3 & NIZ-4 endothermic peak of
drug disappeared, indicating that there might be potential interaction between Nizatidine&
citric acid i.e. Nizatidine is incompatible with citric acid.
From both FT-IR & DSC studies it  was concluded that  Nizatidine is incompatible
with citric acid. Whenever both ingredients are present the scope of brown coloration started.
Not clear in immediately after preparation and after one day, but gradually developed. When
either of the ingredients citric acid or drug is excluded no coloration was noticed. This clearly
proved the interaction between these two ingredients (Nizatidine & citric acid).
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7.3. PHYSICAL PROPERTIES OF PREPARED POWDER BLENDS
The physical properties like Compressibility index (CI), Angle of repose and Hausner
ratio were calculated and tabulated.
Table 7.4: Physical properties of powder blends of tablet formulations
Formulation Angle of repose Compressibility index (%) Hausner ratio
F2 26.85±0.5 15.71±0.2 1.187
F3 25.09±O.9 14.28±0.1 1.166
F4 24.82±1.2 13.95±0.7 1.162
F5 24.87±0.6 15.00±1.6 1.176
F6 25.64±1.O 14.28±1.2 1.166
F7 26.34±0.6 14.98±0.5 1.171
The above tests are not performed for formulation F1 because of interaction between
Nizatidine and citric acid. The results of the physical tests of F2 to F7 of the blend were
within the limits and complied with the standards.
7.4.  EVALUATION  OF  POST  COMPRESSION  PARAMETERS  OF  FLOATING
TABLETS OF NIZATIDINE
All  the  prepared  formulations  were  tested  for  physical  parameters  like  weight
variation, hardness, thickness, friability and found to be within the Pharmacopoeial limits.
The results of the tests are tabulated. The drug content (assay) of all the formulations was
determined and was found to be within the permissible limit. This study indicated that all the
prepared formulations were good.
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(e) (f)
(h)
(i) (j)
FF (l)
(m) (n)
Table 7.5: post compression parameters of Nizatidine floating tablets
7.5. FLOATING PROPERTIES OF NIZATIDINE FLOATING TABLETS
All the formulations were tested for floating properties like floating lag time and total 
floating time. All the batches showed good in vitro buoyancy.
        Table 7.6: Floating properties of Nizatidine floating tablets
Formulation
code
Floating Lag
time
(sec)
Total floating time
(hours)
F2 92 10.1
F3 85 10.4
F4 65 6.8
F5 83 8.2
F6 114 10.5
F7 171 10.1
7.6. IN VITRO DRUG RELEASE STUDIES OF PREPARED FORMULATIONS
7.6.1. Release profiles of formulations containing HPMC K4M
Table 7.7: Cumulative percentage drug release from formulations containing HPMC
K4M
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Formulatio
n code
     Weight 
variation (mg)
Hardness
(kg/cm2)
Thickness
(mm)
Friability
(%)
Assay
(%)
F2 501.5 ± 7.83 6.1 ± 0.2 6.13 ± 0.04 0.18 98.3
F3 500.5 ± 7.24 5.9 ± 0.4 6.16 ± 0.04 0.19 98.9
F4 507 ± 8.56 6.1 ± 0.3 6.30 ± 0.03 0.18 99.28
F5 506.5 ± 10.28 6.2 ± 0.2 6.34 ± 0.04 0.20 97.48
F6 504.5 ± 10.91 5.9 ± 0.3 6.32 ± 0.04 0.17 98.96
F7 504.5 ± 8.64 6.1  ± 0.2 6.33 ± 0.04 0.18 98.29
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20
40
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 Figure 7.8: Cumulative percentage drug release profiles of F2, F3  formulations
containing HPMCK4M
The figure 7.8 suggested the cumulative percentage of drug release from formulations
F2 and F3 was 98.25 ± 1.4 and 93.13 ± 1.4 in 10 hours respectively.
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Time (hours)
Cumulative percentage drug release (%)
Theoretical 
release
F2 F3        -
0 0 0        0
0.5 18.36±1.2 17.25±1.1      15. -
1 23.99±0.3 22.26±1.3 19.25
2 31.04±0.9 27.69±0.7 28.14
3 38.10±1.8 35.65±1.8 37.03
4 44.81±2.6 43.19±2.9 45.92
6 63.23±3.0 57.82±1.1 63.7
8 79.03±2.9 74.86±1.6 81.48
10 98.25±1.4 93.13±1.4 100
These  two formulations  (F2  & F3)  also  floated  for  10  hrs.  Formulations  F3  was
unable  to  sustain  the  drug release  as  theoretical  profile  but  released  the  drug  within  the
desired  time.  Formulations  F2  sustained  the  drug  release  as  theoretical  profile  and  also
released  the  drug  within  the  desired  time.  So  formulation  F2 was  considered  as  best
formulation among all these. The difference in the drug release profiles of the formulations
was due to the presence of different concentrations of polymer. 
Figure 7.9:Cumulative percentage drug release profiles of formulations containing
Polyox WSR 1105
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Time (hours)
Cumulative percentage drug release (%)
F4 F5 F6 F7
0 0 0 0 0
0.5 43.94±3.5 28.11±1.5 17.22±2.4 11.66±0.7
1 51.00±2.5 32.83±1.6 19.98±1.9 15.13±0.7
2 62.54±3.4 43.23±2.8 26.61±2.5 21.94±0.7
3 74.63±3.6 53.12±4.0 37.03±1.8 31.41±0.2
4 86.33±4.0 64.50±3.32 45.69±1.4 39.05±0.1
6 99.62±1.7 83.20±3.5 66.57±3.8 61.23±2.8
8 100.85±1.0 83.90±3.7 79.06±0.9
10 98.41±1.4 97.19±0.4
From  figure  7.9  it  could  be  observed  that  the  polymer  polyox  WSR  1105  had
sustaining effect on the release of drug from the floating matrix tablet. Cumulative percentage
of drug release from formulations F4, F5, F6 and F7 were 99.62 ± 1.7, 100.85 ± 1.0, 98.41 ±
1.4 and 97.19 ± 0.4 in 6, 8, 10 and 10 hours respectively.
Formulations F4 & F5 were unable to sustain the drug release as theoretical profile
and  also  didn’t  release  the  drug  for  the  desired  time  (6  hours&  8  hours  respectively).
Formulations F6 & F7 were able to sustain the drug release as theoretical profile and also
released  the drug  within  the desired  time.  The difference  in  the  drug  release profiles  of
various  formulations  was  due  to  the  presence  of  different  concentrations  of  polymer.
Formulations F6 was considered as best formulation among all the four formulations as it
showed good sustained release very near to theoretical release profile.
7.7. STABILITY STUDIES
 ⁰The optimized formulation was subjected to stability studies at  40 C ± 2oC/ 75%±5
RH for 3 months .
 The  F6 Formulation was evaluated for the physical characteristics, drug content and
In vitro  drug release profile over a period of 3 months.
   
7.10. DRUG CONTENT AND PHYSICAL Parameters OF FORMULATION F6
S.No. Time Physical Parameters % Drug Content ± SD
(40±2⁰C/75±5%RH)
1. 15 days No change 98.86 ± 0.82
2. 1 month No change 98.90 ± 0.30
3. 2 month No change 98.89 ± 0.51
4. 3 month No change 98.96 ± 0.40
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7.11. In vitro % drug Release of Nizatidine (F6) after 3 months stability studies: 
S.No. Time (hrs) Cumulative % Drug Released ± SD   at
40±2⁰C/75±5%RH
1st Day 90th Day
1. 0 0 0
2. 0.5 17.14±1.4 17.19±2.4
3. 1 19.65±0.9 19.87±1.9
4. 2 26.49±2.5 26.61±2.5
5. 3 36.75±1.8 37.00±1.8
6. 4 45.17±1.5 45.67±1.5
7. 6 65.04±2.8 66.54±3.8
                8                  8         82.89±2.7         83.90±3.7
9
                   10           98.43±0.4           98.40±0.4
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8. SUMMARY & CONCLUSION:
 Nizatidine  floating  tablets  were  successfully  prepared  with  hydrophilic  polymers  like
HPMC K4M and Poly Ethylene Oxide WSR 1105
.
 All formulations were evaluated for Compressibility Index, Angle of repose and Hausner
ratio.  The  results  indicated  that  the  final  blend  had  good  flow and  suited  for  direct
compression technique. 
 From the pre-formulation studies for drug excipient compatibility it was observed that
Nizatidine  had  interaction  with  citric  acid.  No  physical  or  chemical  incompatibility
existed between the drug and other excipients.
 All formulations were tested for post compression parameters like hardness, thickness,
weight variation, friability and drug content. All estimated parameters were found to be
within the limits. This indicated that all the prepared formulations were good.
 All  formulations  were  tested  for  buoyancy  properties  like  floating  lag  time  &  total
floating time. Almost all the formulations showed satisfactory results.
 All formulations were tested for in vitro drug release. The optimized formulations among
HPMC K4M and  Poly Ethylene Oxide WSR 1105  are F2 and F6. These were chosen
because of their close similarity with predicted theoretical release profile.
 The F6 formulation was chosen as the best formulation among all the  other formulations.
So stability studies are performed after one month also the formulation is stable .
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